JP2017142265A - ポイントオブケア流体システムおよびその使用 - Google Patents
ポイントオブケア流体システムおよびその使用 Download PDFInfo
- Publication number
- JP2017142265A JP2017142265A JP2017085342A JP2017085342A JP2017142265A JP 2017142265 A JP2017142265 A JP 2017142265A JP 2017085342 A JP2017085342 A JP 2017085342A JP 2017085342 A JP2017085342 A JP 2017085342A JP 2017142265 A JP2017142265 A JP 2017142265A
- Authority
- JP
- Japan
- Prior art keywords
- sample
- item
- fluidic device
- assay
- analyte
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012530 fluid Substances 0.000 title description 94
- 238000000034 method Methods 0.000 abstract description 251
- 238000004891 communication Methods 0.000 abstract description 52
- 239000013060 biological fluid Substances 0.000 abstract description 27
- 230000005540 biological transmission Effects 0.000 abstract description 13
- 238000012123 point-of-care testing Methods 0.000 abstract description 7
- 238000011897 real-time detection Methods 0.000 abstract description 2
- 239000000523 sample Substances 0.000 description 295
- 238000003556 assay Methods 0.000 description 165
- 239000012491 analyte Substances 0.000 description 158
- 210000001124 body fluid Anatomy 0.000 description 125
- 239000003153 chemical reaction reagent Substances 0.000 description 110
- 239000003814 drug Substances 0.000 description 106
- 238000006243 chemical reaction Methods 0.000 description 87
- 239000010839 body fluid Substances 0.000 description 75
- 238000003018 immunoassay Methods 0.000 description 75
- 229940079593 drug Drugs 0.000 description 69
- 239000000376 reactant Substances 0.000 description 61
- 238000001514 detection method Methods 0.000 description 54
- 230000000144 pharmacologic effect Effects 0.000 description 53
- 108091006146 Channels Proteins 0.000 description 41
- XNRNNGPBEPRNAR-UHFFFAOYSA-N Thromboxane B2 Natural products CCCCCC(O)C=CC1OC(O)CC(O)C1CC=CCCCC(O)=O XNRNNGPBEPRNAR-UHFFFAOYSA-N 0.000 description 29
- 229940124597 therapeutic agent Drugs 0.000 description 29
- XNRNNGPBEPRNAR-JQBLCGNGSA-N thromboxane B2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1OC(O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O XNRNNGPBEPRNAR-JQBLCGNGSA-N 0.000 description 29
- 239000000090 biomarker Substances 0.000 description 27
- 238000011282 treatment Methods 0.000 description 27
- 230000009471 action Effects 0.000 description 26
- 238000004458 analytical method Methods 0.000 description 26
- 210000004369 blood Anatomy 0.000 description 25
- 239000008280 blood Substances 0.000 description 25
- 201000010099 disease Diseases 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 22
- 230000003285 pharmacodynamic effect Effects 0.000 description 21
- 102000004190 Enzymes Human genes 0.000 description 19
- 108090000790 Enzymes Proteins 0.000 description 19
- 230000008901 benefit Effects 0.000 description 19
- 229940088598 enzyme Drugs 0.000 description 19
- 230000008859 change Effects 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 17
- -1 specimen Substances 0.000 description 17
- 239000000758 substrate Substances 0.000 description 17
- 239000002699 waste material Substances 0.000 description 17
- 238000010171 animal model Methods 0.000 description 16
- 238000004519 manufacturing process Methods 0.000 description 16
- 239000000463 material Substances 0.000 description 16
- 238000012544 monitoring process Methods 0.000 description 16
- 230000008569 process Effects 0.000 description 16
- 238000011084 recovery Methods 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 239000007788 liquid Substances 0.000 description 14
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 13
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 230000035945 sensitivity Effects 0.000 description 12
- 231100000419 toxicity Toxicity 0.000 description 12
- 230000001988 toxicity Effects 0.000 description 12
- 230000006870 function Effects 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 230000003287 optical effect Effects 0.000 description 11
- 238000012545 processing Methods 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 238000004364 calculation method Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000003446 ligand Substances 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 10
- 229920000642 polymer Polymers 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 238000013461 design Methods 0.000 description 9
- 239000003550 marker Substances 0.000 description 9
- 239000002207 metabolite Substances 0.000 description 9
- 229910052751 metal Inorganic materials 0.000 description 9
- 239000002184 metal Substances 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 238000003860 storage Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 238000004422 calculation algorithm Methods 0.000 description 8
- 231100000673 dose–response relationship Toxicity 0.000 description 8
- 239000002359 drug metabolite Substances 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 238000013459 approach Methods 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 231100001274 therapeutic index Toxicity 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 230000007704 transition Effects 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 239000004020 conductor Substances 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 150000004676 glycans Chemical class 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000005424 photoluminescence Methods 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- 239000011148 porous material Substances 0.000 description 6
- 238000000611 regression analysis Methods 0.000 description 6
- 238000005070 sampling Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 108010088751 Albumins Proteins 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 5
- 108010074051 C-Reactive Protein Proteins 0.000 description 5
- 102100032752 C-reactive protein Human genes 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 102000003886 Glycoproteins Human genes 0.000 description 5
- 108090000288 Glycoproteins Proteins 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 238000011088 calibration curve Methods 0.000 description 5
- 238000012767 chemiluminescent enzyme immunoassay Methods 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 5
- 238000012875 competitive assay Methods 0.000 description 5
- 239000003599 detergent Substances 0.000 description 5
- 230000005284 excitation Effects 0.000 description 5
- 210000003722 extracellular fluid Anatomy 0.000 description 5
- 239000007850 fluorescent dye Substances 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- 150000002739 metals Chemical class 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 229910052710 silicon Inorganic materials 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 102400000630 Acylation stimulating protein Human genes 0.000 description 4
- 101800000415 Acylation stimulating protein Proteins 0.000 description 4
- 206010003805 Autism Diseases 0.000 description 4
- 208000020706 Autistic disease Diseases 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 4
- 102100038358 Prostate-specific antigen Human genes 0.000 description 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 4
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 4
- 239000012131 assay buffer Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 230000000593 degrading effect Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000002651 drug therapy Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000004020 luminiscence type Methods 0.000 description 4
- 230000002934 lysing effect Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 210000002307 prostate Anatomy 0.000 description 4
- 102000029752 retinol binding Human genes 0.000 description 4
- 108091000053 retinol binding Proteins 0.000 description 4
- 239000010703 silicon Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
- 239000011534 wash buffer Substances 0.000 description 4
- 238000003466 welding Methods 0.000 description 4
- 102100025674 Angiopoietin-related protein 4 Human genes 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 3
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 102000030914 Fatty Acid-Binding Human genes 0.000 description 3
- 102100030431 Fatty acid-binding protein, adipocyte Human genes 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 241000588747 Klebsiella pneumoniae Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102100037765 Periostin Human genes 0.000 description 3
- 101710199268 Periostin Proteins 0.000 description 3
- 241000191940 Staphylococcus Species 0.000 description 3
- 108010000499 Thromboplastin Proteins 0.000 description 3
- 102000002262 Thromboplastin Human genes 0.000 description 3
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000009137 competitive binding Effects 0.000 description 3
- 238000005401 electroluminescence Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 230000005281 excited state Effects 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 108091022862 fatty acid binding Proteins 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 230000005021 gait Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000002974 pharmacogenomic effect Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229920001690 polydopamine Polymers 0.000 description 3
- 229920000307 polymer substrate Polymers 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 208000011117 substance-related disease Diseases 0.000 description 3
- 230000002277 temperature effect Effects 0.000 description 3
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 2
- KGLPWQKSKUVKMJ-UHFFFAOYSA-N 2,3-dihydrophthalazine-1,4-dione Chemical class C1=CC=C2C(=O)NNC(=O)C2=C1 KGLPWQKSKUVKMJ-UHFFFAOYSA-N 0.000 description 2
- RNIPJYFZGXJSDD-UHFFFAOYSA-N 2,4,5-triphenyl-1h-imidazole Chemical compound C1=CC=CC=C1C1=NC(C=2C=CC=CC=2)=C(C=2C=CC=CC=2)N1 RNIPJYFZGXJSDD-UHFFFAOYSA-N 0.000 description 2
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 2
- 102000054930 Agouti-Related Human genes 0.000 description 2
- 101710127426 Agouti-related protein Proteins 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 2
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 2
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 2
- 108010075254 C-Peptide Proteins 0.000 description 2
- 101100496968 Caenorhabditis elegans ctc-1 gene Proteins 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 102100022641 Coagulation factor IX Human genes 0.000 description 2
- 102100023804 Coagulation factor VII Human genes 0.000 description 2
- 239000003154 D dimer Substances 0.000 description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
- ZAHDXEIQWWLQQL-IHRRRGAJSA-N Deoxypyridinoline Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(O)=C(C[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 ZAHDXEIQWWLQQL-IHRRRGAJSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108010076282 Factor IX Proteins 0.000 description 2
- 108010023321 Factor VII Proteins 0.000 description 2
- 108010014173 Factor X Proteins 0.000 description 2
- 108010080865 Factor XII Proteins 0.000 description 2
- 102000000429 Factor XII Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 241000606768 Haemophilus influenzae Species 0.000 description 2
- 101001062864 Homo sapiens Fatty acid-binding protein, adipocyte Proteins 0.000 description 2
- 101001013832 Homo sapiens Mitochondrial peptide methionine sulfoxide reductase Proteins 0.000 description 2
- 101000597785 Homo sapiens Tumor necrosis factor receptor superfamily member 6B Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 238000012773 Laboratory assay Methods 0.000 description 2
- 108010092277 Leptin Proteins 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- 102100031775 Leptin receptor Human genes 0.000 description 2
- 108010028275 Leukocyte Elastase Proteins 0.000 description 2
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000003792 Metallothionein Human genes 0.000 description 2
- 108090000157 Metallothionein Proteins 0.000 description 2
- 102100031767 Mitochondrial peptide methionine sulfoxide reductase Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102400000569 Myeloperoxidase Human genes 0.000 description 2
- 108090000235 Myeloperoxidases Proteins 0.000 description 2
- 102100030856 Myoglobin Human genes 0.000 description 2
- 108010062374 Myoglobin Proteins 0.000 description 2
- 101100221647 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cox-1 gene Proteins 0.000 description 2
- 102100033174 Neutrophil elastase Human genes 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 102000004067 Osteocalcin Human genes 0.000 description 2
- 108090000573 Osteocalcin Proteins 0.000 description 2
- 102000008108 Osteoprotegerin Human genes 0.000 description 2
- 108010035042 Osteoprotegerin Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 101150062589 PTGS1 gene Proteins 0.000 description 2
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 2
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 2
- 102000018967 Platelet-Derived Growth Factor beta Receptor Human genes 0.000 description 2
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 108010050808 Procollagen Proteins 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 2
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 108010007127 Pulmonary Surfactant-Associated Protein D Proteins 0.000 description 2
- 102100027845 Pulmonary surfactant-associated protein D Human genes 0.000 description 2
- 102000013674 S-100 Human genes 0.000 description 2
- 108700021018 S100 Proteins 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 102000013394 Troponin I Human genes 0.000 description 2
- 108010065729 Troponin I Proteins 0.000 description 2
- 102000004987 Troponin T Human genes 0.000 description 2
- 108090001108 Troponin T Proteins 0.000 description 2
- 102100035284 Tumor necrosis factor receptor superfamily member 6B Human genes 0.000 description 2
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 238000005415 bioluminescence Methods 0.000 description 2
- 230000029918 bioluminescence Effects 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000005229 chemical vapour deposition Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 206010013663 drug dependence Diseases 0.000 description 2
- 230000008406 drug-drug interaction Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000009713 electroplating Methods 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 238000005530 etching Methods 0.000 description 2
- 108010052295 fibrin fragment D Proteins 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229940047650 haemophilus influenzae Drugs 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001746 injection moulding Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229940039781 leptin Drugs 0.000 description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
- 108010019813 leptin receptors Proteins 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000955 prescription drug Substances 0.000 description 2
- 150000003815 prostacyclins Chemical class 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000036387 respiratory rate Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 239000004065 semiconductor Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 229960000278 theophylline Drugs 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 150000003595 thromboxanes Chemical class 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- URJOZSLMTIRWFW-QGZVFWFLSA-N (4r)-4-(1,3-benzodioxol-5-yl)-5,6-dimethoxy-4,9-dihydro-1h-benzo[f][2]benzofuran-3-one Chemical compound C1=C2OCOC2=CC([C@H]2C3=C(COC3=O)CC3=CC=C(C(=C32)OC)OC)=C1 URJOZSLMTIRWFW-QGZVFWFLSA-N 0.000 description 1
- BQCIDUSAKPWEOX-UHFFFAOYSA-N 1,1-Difluoroethene Chemical compound FC(F)=C BQCIDUSAKPWEOX-UHFFFAOYSA-N 0.000 description 1
- MPCAJMNYNOGXPB-SLPGGIOYSA-N 1,5-anhydro-D-glucitol Chemical compound OC[C@H]1OC[C@H](O)[C@@H](O)[C@@H]1O MPCAJMNYNOGXPB-SLPGGIOYSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- KIWODJBCHRADND-UHFFFAOYSA-N 3-anilino-4-[1-[3-(1-imidazolyl)propyl]-3-indolyl]pyrrole-2,5-dione Chemical compound O=C1NC(=O)C(C=2C3=CC=CC=C3N(CCCN3C=NC=C3)C=2)=C1NC1=CC=CC=C1 KIWODJBCHRADND-UHFFFAOYSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- KFGOFTHODYBSGM-IJCBKZNRSA-N 6-Keto-prostaglandin F1a Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC(=O)CCCCC(O)=O KFGOFTHODYBSGM-IJCBKZNRSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- 101150054149 ANGPTL4 gene Proteins 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 102100031786 Adiponectin Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 102400001318 Adrenomedullin Human genes 0.000 description 1
- 101800004616 Adrenomedullin Proteins 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 108700042530 Angiopoietin-Like Protein 4 Proteins 0.000 description 1
- 102100025668 Angiopoietin-related protein 3 Human genes 0.000 description 1
- 101710085845 Angiopoietin-related protein 4 Proteins 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 102000018616 Apolipoproteins B Human genes 0.000 description 1
- 108010027006 Apolipoproteins B Proteins 0.000 description 1
- 102000013933 Apolipoproteins D Human genes 0.000 description 1
- 108010025614 Apolipoproteins D Proteins 0.000 description 1
- 108010025628 Apolipoproteins E Proteins 0.000 description 1
- 102100021723 Arginase-1 Human genes 0.000 description 1
- 101710129000 Arginase-1 Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 229940124638 COX inhibitor Drugs 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- 102100031277 Calcineurin B homologous protein 1 Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZKQDCIXGCQPQNV-UHFFFAOYSA-N Calcium hypochlorite Chemical compound [Ca+2].Cl[O-].Cl[O-] ZKQDCIXGCQPQNV-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 102100028892 Cardiotrophin-1 Human genes 0.000 description 1
- 102000055007 Cartilage Oligomeric Matrix Human genes 0.000 description 1
- 108700005376 Cartilage Oligomeric Matrix Proteins 0.000 description 1
- 102000004171 Cathepsin K Human genes 0.000 description 1
- 108090000625 Cathepsin K Proteins 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010075016 Ceruloplasmin Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 108010038447 Chromogranin A Proteins 0.000 description 1
- 102000010792 Chromogranin A Human genes 0.000 description 1
- 241000588923 Citrobacter Species 0.000 description 1
- 102100029117 Coagulation factor X Human genes 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 1
- 108010061642 Cystatin C Proteins 0.000 description 1
- 102000012192 Cystatin C Human genes 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
- BVTJGGGYKAMDBN-UHFFFAOYSA-N Dioxetane Chemical class C1COO1 BVTJGGGYKAMDBN-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 102400001047 Endostatin Human genes 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 1
- 206010072063 Exposure to lead Diseases 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010074864 Factor XI Proteins 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 102100030421 Fatty acid-binding protein 5 Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 229910005540 GaP Inorganic materials 0.000 description 1
- 229910001218 Gallium arsenide Inorganic materials 0.000 description 1
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 description 1
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- 102400000442 Ghrelin-28 Human genes 0.000 description 1
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
- 102400000320 Glicentin Human genes 0.000 description 1
- 101800002945 Glicentin Proteins 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 1
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 description 1
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 102000007390 Glycogen Phosphorylase Human genes 0.000 description 1
- 108010046163 Glycogen Phosphorylase Proteins 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 102100033851 Gonadotropin-releasing hormone receptor Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241000606766 Haemophilus parainfluenzae Species 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010019773 Hepatitis G Diseases 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- 108010000487 High-Molecular-Weight Kininogen Proteins 0.000 description 1
- 102000000543 Histamine Receptors Human genes 0.000 description 1
- 108010002059 Histamine Receptors Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000693085 Homo sapiens Angiopoietin-related protein 3 Proteins 0.000 description 1
- 101000693076 Homo sapiens Angiopoietin-related protein 4 Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101001062855 Homo sapiens Fatty acid-binding protein 5 Proteins 0.000 description 1
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 1
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 1
- 101001024605 Homo sapiens Next to BRCA1 gene 1 protein Proteins 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 102100035792 Kininogen-1 Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 108010021290 LHRH Receptors Proteins 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 102100030335 Midkine Human genes 0.000 description 1
- 108010092801 Midkine Proteins 0.000 description 1
- 102100023123 Mucin-16 Human genes 0.000 description 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- 108010056852 Myostatin Proteins 0.000 description 1
- 101150111783 NTRK1 gene Proteins 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102100037600 P2Y purinoceptor 1 Human genes 0.000 description 1
- 101150000187 PTGS2 gene Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 108030001694 Pappalysin-1 Proteins 0.000 description 1
- 102100029909 Peptide YY Human genes 0.000 description 1
- 108010088847 Peptide YY Proteins 0.000 description 1
- 108700020962 Peroxidase Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- ZPHBZEQOLSRPAK-UHFFFAOYSA-N Phosphoramidon Natural products C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O ZPHBZEQOLSRPAK-UHFFFAOYSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108090000113 Plasma Kallikrein Proteins 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 102000004211 Platelet factor 4 Human genes 0.000 description 1
- 108090000778 Platelet factor 4 Proteins 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 241000233872 Pneumocystis carinii Species 0.000 description 1
- 102100036143 Polycystin-1 Human genes 0.000 description 1
- 101710146367 Polycystin-1 Proteins 0.000 description 1
- 101710146368 Polycystin-2 Proteins 0.000 description 1
- 102100036142 Polycystin-2 Human genes 0.000 description 1
- 108010071690 Prealbumin Proteins 0.000 description 1
- 102000007584 Prealbumin Human genes 0.000 description 1
- 102000005819 Pregnancy-Associated Plasma Protein-A Human genes 0.000 description 1
- 108010048233 Procalcitonin Proteins 0.000 description 1
- 102000015433 Prostaglandin Receptors Human genes 0.000 description 1
- 108010050183 Prostaglandin Receptors Proteins 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102100024923 Protein kinase C beta type Human genes 0.000 description 1
- 101710094033 Protein kinase C beta type Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 description 1
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 description 1
- 108010085249 Purinergic P2 Receptors Proteins 0.000 description 1
- LCYXYLLJXMAEMT-SAXRGWBVSA-N Pyridinoline Chemical compound OC(=O)[C@@H](N)CCC1=C[N+](C[C@H](O)CC[C@H](N)C([O-])=O)=CC(O)=C1C[C@H](N)C(O)=O LCYXYLLJXMAEMT-SAXRGWBVSA-N 0.000 description 1
- 108010025832 RANK Ligand Proteins 0.000 description 1
- 102000014128 RANK Ligand Human genes 0.000 description 1
- 102000007156 Resistin Human genes 0.000 description 1
- 108010047909 Resistin Proteins 0.000 description 1
- 101710102802 Runt-related transcription factor 2 Proteins 0.000 description 1
- 101000744436 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Trans-acting factor D Proteins 0.000 description 1
- 102400000827 Saposin-D Human genes 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- 101710149279 Small delta antigen Proteins 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000122973 Stenotrophomonas maltophilia Species 0.000 description 1
- 241000529895 Stercorarius Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 102000007591 Tartrate-Resistant Acid Phosphatase Human genes 0.000 description 1
- 108010032050 Tartrate-Resistant Acid Phosphatase Proteins 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000007238 Transferrin Receptors Human genes 0.000 description 1
- 108010033576 Transferrin Receptors Proteins 0.000 description 1
- 241000224526 Trichomonas Species 0.000 description 1
- 208000005448 Trichomonas Infections Diseases 0.000 description 1
- 206010044620 Trichomoniasis Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108060005989 Tryptase Proteins 0.000 description 1
- 102000001400 Tryptase Human genes 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 102100040613 Uromodulin Human genes 0.000 description 1
- 108010027007 Uromodulin Proteins 0.000 description 1
- 102000003848 Uteroglobin Human genes 0.000 description 1
- 108090000203 Uteroglobin Proteins 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- HZEWFHLRYVTOIW-UHFFFAOYSA-N [Ti].[Ni] Chemical compound [Ti].[Ni] HZEWFHLRYVTOIW-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 208000012761 aggressive behavior Diseases 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000003928 amperometric titration Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000002587 anti-hemolytic effect Effects 0.000 description 1
- 230000003460 anti-nuclear Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000009833 antibody interaction Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229910052787 antimony Inorganic materials 0.000 description 1
- WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 244000078885 bloodborne pathogen Species 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000000233 bronchiolar non-ciliated Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 108010041776 cardiotrophin 1 Proteins 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 108010049937 collagen type I trimeric cross-linked peptide Proteins 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000002967 competitive immunoassay Methods 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 150000002013 dioxins Chemical class 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 239000013536 elastomeric material Substances 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 238000000407 epitaxy Methods 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229940012413 factor vii Drugs 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 229940012444 factor xiii Drugs 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000011152 fibreglass Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940049370 fibrinolysis inhibitor Drugs 0.000 description 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000003067 hemagglutinative effect Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 239000003219 hemolytic agent Substances 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 108010011705 herstatin Proteins 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005468 ion implantation Methods 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 238000010030 laminating Methods 0.000 description 1
- 238000010329 laser etching Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 229940002661 lipitor Drugs 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000001459 lithography Methods 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- KNJDBYZZKAZQNG-UHFFFAOYSA-N lucigenin Chemical compound [O-][N+]([O-])=O.[O-][N+]([O-])=O.C12=CC=CC=C2[N+](C)=C(C=CC=C2)C2=C1C1=C(C=CC=C2)C2=[N+](C)C2=CC=CC=C12 KNJDBYZZKAZQNG-UHFFFAOYSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000006247 magnetic powder Substances 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000004377 microelectronic Methods 0.000 description 1
- 238000001393 microlithography Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 108010065887 myosin light chain I Proteins 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910001000 nickel titanium Inorganic materials 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 125000003431 oxalo group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 238000000206 photolithography Methods 0.000 description 1
- 229920002120 photoresistant polymer Polymers 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000001020 plasma etching Methods 0.000 description 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 102000005162 pleiotrophin Human genes 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 229920000131 polyvinylidene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- WHALSQRTWNBBCV-UHFFFAOYSA-N s-aminosulfanylthiohydroxylamine Chemical compound NSSN WHALSQRTWNBBCV-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000007650 screen-printing Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000002210 silicon-based material Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical group [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000012306 spectroscopic technique Methods 0.000 description 1
- 238000004544 sputter deposition Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000026676 system process Effects 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- ZBBCUBMBMZNEME-QBGWIPKPSA-L ticarcillin disodium Chemical compound [Na+].[Na+].C=1([C@@H](C([O-])=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)C=CSC=1 ZBBCUBMBMZNEME-QBGWIPKPSA-L 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 1
- 229940087652 vioxx Drugs 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 238000003631 wet chemical etching Methods 0.000 description 1
- 238000007704 wet chemistry method Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/76—Chemiluminescence; Bioluminescence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/14—Devices for taking samples of blood ; Measuring characteristics of blood in vivo, e.g. gas concentration within the blood, pH-value of blood
- A61B5/1405—Devices for taking blood samples
- A61B5/1411—Devices for taking blood samples by percutaneous method, e.g. by lancet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/14—Devices for taking samples of blood ; Measuring characteristics of blood in vivo, e.g. gas concentration within the blood, pH-value of blood
- A61B5/1405—Devices for taking blood samples
- A61B5/1427—Multiple blood sampling, e.g. at periodic or pre-established intervals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/151—Devices specially adapted for taking samples of capillary blood, e.g. by lancets, needles or blades
- A61B5/15142—Devices intended for single use, i.e. disposable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/157—Devices characterised by integrated means for measuring characteristics of blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
- A61B5/412—Detecting or monitoring sepsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
- A61B5/414—Evaluating particular organs or parts of the immune or lymphatic systems
- A61B5/417—Evaluating particular organs or parts of the immune or lymphatic systems the bone marrow
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
- B01L3/50273—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by the means or forces applied to move the fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5302—Apparatus specially adapted for immunological test procedures
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1495—Calibrating or testing of in-vivo probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150015—Source of blood
- A61B5/150022—Source of blood for capillary blood or interstitial fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150053—Details for enhanced collection of blood or interstitial fluid at the sample site, e.g. by applying compression, heat, vibration, ultrasound, suction or vacuum to tissue; for reduction of pain or discomfort; Skin piercing elements, e.g. blades, needles, lancets or canulas, with adjustable piercing speed
- A61B5/150061—Means for enhancing collection
- A61B5/150099—Means for enhancing collection by negative pressure, other than vacuum extraction into a syringe by pulling on the piston rod or into pre-evacuated tubes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150206—Construction or design features not otherwise provided for; manufacturing or production; packages; sterilisation of piercing element, piercing device or sampling device
- A61B5/150251—Collection chamber divided into at least two compartments, e.g. for division of samples
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150763—Details with identification means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150847—Communication to or from blood sampling device
- A61B5/150854—Communication to or from blood sampling device long distance, e.g. between patient's home and doctor's office
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/02—Identification, exchange or storage of information
- B01L2300/021—Identification, e.g. bar codes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/02—Identification, exchange or storage of information
- B01L2300/023—Sending and receiving of information, e.g. using bluetooth
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/04—Closures and closing means
- B01L2300/041—Connecting closures to device or container
- B01L2300/044—Connecting closures to device or container pierceable, e.g. films, membranes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0627—Sensor or part of a sensor is integrated
- B01L2300/0636—Integrated biosensor, microarrays
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0809—Geometry, shape and general structure rectangular shaped
- B01L2300/0816—Cards, e.g. flat sample carriers usually with flow in two horizontal directions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
- B01L2300/0867—Multiple inlets and one sample wells, e.g. mixing, dilution
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
- B01L2300/087—Multiple sequential chambers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
- B01L2300/0877—Flow chambers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
- B01L2300/0883—Serpentine channels
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0887—Laminated structure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/11—Automated chemical analysis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/11—Automated chemical analysis
- Y10T436/115831—Condition or time responsive
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/12—Condition responsive control
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
Abstract
Description
本出願は、2005年5月9日に出願された米国仮特許出願第60/678,801号、2005年8月5日に出願された米国仮特許出願第60/705,489号、2005年9月16日に出願された米国仮特許出願第60/717,192号、および2005年9月28日に出願された米国仮特許出願第60/721,097号の利益を請求しており、それらはすべてその全体が本明細書中に参考として援用される。
本発明は医療デバイスの分野である。特に、本発明は、生体液からの検体を実時間で検出することが可能である携帯用医療デバイスを提供する。方法およびデバイスは、様々な医学的応用のためのポイントオブケア(point−of−care)検査を行うのに特に有用である。
膨大な数の疾病バイオマーカーの発見および微小マイクロ流体システムの設置は、新しい手段を開拓し、ポイントオブケア設定において疾病の予見、診断および治療のための方法およびシステムを考案してきた。ポイントオブケア検査は、結果を速やかに医療実務者に伝え、診察を早くすることができるので特に望ましい。初期診断により医療実務者は治療をより早く開始することができ、それにより付き添いの患者の状態の退歩を回避することができる。ポイントオブケア分析の実例には、グルコース検査、薬物の不正使用、血清コレステロール、妊娠、および排卵が含まれる。しかしながら、これらならびに現在使用できる他のポイントオブケア方法およびシステムは、サンプル採取、検査、分析および必要なときに医療実務者または保健提供者へ結果を伝達するための統合的解決法を提供しない。従って、オンラインの医療診察または意思決定と同様に、便利で迅速なデータ収集、伝送、分析を提供する携帯用多重パラメーター測定機器の注目に値する必要性が残る。
本発明の一側面は、患者と医療実務者との間の実時間データ伝送を提供し、歩行用の設定において高処理能力ポイントオブケア検査を容易にすることができるシステムの設計である。本明細書に提供している前記システムおよび方法は、実験室の備品または設備を使用することなく、被験体(例えば、患者)から収集されたサンプルを処理および分析する、骨の折れる、また費用のかかる手順を簡略化する。前記システムおよび方法は、診断、予後診断、治療、および治療法の開発を開始するために、体液の小さなサンプルから検体を検出するのに特に有用である。
本発明はまた、以下の項目を提供する。
(項目1)
被験体からの体液中の検体を検出するためのシステムであって、
a)流体デバイスであって、サンプル収集ユニットおよびアッセイアセンブリを備え、該サンプル収集ユニットは、体液のサンプルを、外部デバイスから伝送されるプロトコルに基づき該アッセイアセンブリ内に含有されている反応物質と反応させ、該検体の存在を示す検出可能な信号を発生する、流体デバイスと、
b)該検出可能な信号を検出するための検出アセンブリを備える読取機アセンブリと、
c)該検出信号を該外部デバイスへ伝送するための通信アセンブリと、を備える、システム。
(項目2)
上記プロトコルは外部デバイスから無線で伝送される、項目1に記載のシステム。
(項目3)
上記流体デバイスは、上記プロトコルの上記伝送の誘因となるよう適合する該流体デバイスの同一性を与える識別子をさらに備える、項目1に記載のシステム。
(項目4)
上記プロトコルは、識別子検出器によって認識可能な上記流体デバイスの上記同一性に依存して変化する、項目1に記載のシステム。
(項目5)
上記体液のサンプルは約500μl未満である、項目1に記載のシステム。
(項目6)
被験体からの体液中の検体を検出するためのシステムであって、
a)流体デバイスであって、サンプル収集ユニットおよびアッセイアセンブリを備え、該サンプル収集ユニットは、500μl未満の体液のサンプルを該アッセイアセンブリ内に含有されている反応物質と反応させ、該体液のサンプル中の収集された該検体の存在を示す検出可能な信号を発生する、流体デバイスと、
b)該検出可能な信号を検出するための検出アセンブリを備える読取機アセンブリと、
c)該検出信号を外部デバイスへ伝送するための通信アセンブリと、
を備える、システム。
(項目7)
上記反応物質は免疫アッセイ試薬を含む、項目1または6に記載のシステム。
(項目8)
上記免疫アッセイ試薬は、細菌、ウイルス、真菌、および原虫から成る群から選択される微生物を検出する、項目7に記載のシステム。
(項目9)
上記免疫アッセイ試薬は、ポリペプチド糖タンパク質、多糖類、脂質、核酸、およびそれらの組み合わせを検出する、項目7に記載のシステム。
(項目10)
上記免疫アッセイ試薬は、薬物、薬物代謝産物、疾病を示すバイオマーカー、組織特異的マーカー、および細胞または細胞型に対して特異的なバイオマーカーから成る群から選択される要素を検出する、項目7に記載のシステム。
(項目11)
上記流体デバイスは複数の検体を検出し、かつ該流体デバイスは、該複数の検体のために免疫アッセイ試薬を備える、項目1または6に記載のシステム。
(項目12)
上記複数の検体は、3桁の範囲にわたり検出可能な明確な信号によって識別される、項目11に記載のシステム。
(項目13)
上記検出可能な信号は発光信号である、項目7に記載のシステム。
(項目14)
上記流体デバイスは、上記体液のサンプルを採取するための極微針をさらに備える、項目1または6に記載のシステム。
(項目15)
被験体の体液中の検体を検出するための方法であって、
a)項目1または6に記載のシステムを提供するステップと、
b)体液のサンプルを上記アッセイアセンブリ内に含有されている上記反応物質と反応させ、該検体の存在を示す検出可能な信号を発生するステップと、
c)該検出可能な信号を検出するステップと、
を含む、方法。
(項目16)
上記体液中に存在している上記検体の量を定量化するステップをさらに含む、項目15に記載の方法。
(項目17)
上記生体液中に存在している上記検体の上記量を上記検体の所定の量と比較するステップをさらに含む、項目16に記載の方法。
(項目18)
上記体液中に存在している上記検体の上記量が、統計的に上記所定の量と異なる場合は、医療行為を起こすステップをさらに含む、項目15に記載の方法。
(項目19)
上記医療行為は、上記被験体のための処方薬を変える必要があることを薬局に通知するステップを含む、項目18に記載の方法。
(項目20)
上記通知は電子的に伝送される、項目19に記載の方法。
(項目21)
上記通知は無線で伝送される、項目19に記載の方法。
(項目22)
上記医療行為は、被験体の治療薬の用量を変えるステップを含む、項目18に記載の方法。
(項目23)
被験体からの体液中の検体を検出する方法であって、
a)少なくとも1つのサンプル収集ユニット、免疫アッセイ試薬を含有している免疫アッセイアセンブリ、該サンプル収集ユニットおよび/または該免疫アッセイアセンブリと流体連通している複数のチャネルを備える流体デバイスを提供するステップと、
b)該流体デバイスを作動させ、該流体デバイス内の該免疫アッセイ試薬を方向づけるステップと、
c)約500μl未満の体液のサンプルを該アッセイ免疫アッセイアセンブリ内に含有されている該免疫アッセイ試薬と反応させ、該サンプル中の該検体の存在を示す検出可能な信号を発生するステップと、
d)該体液のサンプル中の収集された該検体から生成される該検出可能な信号を検出するステップと、
を含む、方法。
(項目24)
上記方向づけるステップは、毛管作用、真空吸引、引っ張り、およびそれらの組み合わせから成る群から選択される機構によって達成される、項目23に記載の方法。
(項目25)
上記流体デバイスは複数の検体を検出し、かつ該流体デバイスは該複数の検体のために免疫アッセイ試薬を備える、項目23に記載の方法。
(項目26)
上記体液のサンプルおよび上記免疫アッセイ試薬は、上記検出するステップの後も上記流体デバイスにとどまる、項目23に記載の方法。
(項目27)
上記免疫アッセイは薬物動態パラメーターを示す、項目23に記載の方法。
(項目28)
上記免疫アッセイは薬力学的パラメーターを示す、項目23に記載の方法。
(項目29)
上記流体デバイスは、上記信号に関するデータを無線伝送器経由で伝達する、項目23に記載の方法。
(項目30)
無線デバイスは、上記流体デバイスで実施される免疫アッセイプロトコルを転送する、項目23に記載の方法。
(項目31)
上記免疫アッセイプロトコルは、上記流体デバイスの同一性に依存して変化する、項目23に記載の方法。
(項目32)
上記流体デバイスは識別され、そして該流体デバイスの有効期限が登録される、項目23に記載の方法。
(項目33)
上記免疫アッセイは、疾病マーカー、薬物代謝産物および病原体についてのアッセイである、項目23に記載の方法。
(項目34)
上記検出可能な信号は化学発光信号である、項目23に記載の方法。
(項目35)
上記免疫アッセイ試薬は、アルカリホスファターゼまたは西洋ワサビペルオキシダーゼを含む、項目23に記載の方法。
(項目36)
上記検出可能な信号を上記検出するステップのためにCCDを使用する、項目23に記載の方法。
(項目37)
上記流体デバイスは、少なくとも1つのごみ処理機をさらに備える、項目23に記載の方法。
(項目38)
増幅器と接続されたピンダイオードが、上記検出可能な信号を検出するために使用される、項目23に記載の方法。
(項目39)
上記免疫アッセイアセンブリが、複数の免疫アッセイを備える、項目23に記載の方法。
(項目40)
上記流体デバイスは、上記体液のサンプルを採取するために極微針をさらに備える、項目23に記載の方法。
(項目41)
治療薬の有効性および/または毒性を評価するために有用な2つ以上の薬理学的パラメーターを測定するためのシステムであって、
a)カートリッジを備える流体デバイスであって、該カートリッジは少なくとも1つのサンプル収集ユニットおよびアセンブリを備え、該サンプル収集ユニットは、指標となる複数の検体または該2つ以上の薬理学的パラメーターを備える体液のサンプルを、該アッセイアセンブリ内に含有されている反応物質と反応させ、該反応は、該体液のサンプルから該2つ以上の薬理学的パラメーターの値を示す検出可能な信号を発生する、流体デバイスと、
b)該検出可能な信号を検出するための検出アセンブリを備える読取機アセンブリと、
c)該検出信号を外部デバイスへ伝送するための通信アセンブリと、
を備える、システム。
(項目42)
上記流体デバイスは、外部デバイスから伝送されるプロトコルに基づき上記検出可能な信号を発生する、項目41に記載のシステム。
(項目43)
上記プロトコルは無線で伝送される、項目42に記載のシステム。
(項目44)
上記流体デバイスは、上記プロトコルの上記伝送の誘因となるよう適合する該流体デバイスの同一性を与える識別子をさらに備える、項目41に記載のシステム。
(項目45)
上記プロトコルは、識別子検出器によって認識可能な上記流体デバイスの上記同一性に依存して変化する、項目41に記載のシステム。
(項目46)
上記体液のサンプルは約500μl未満である、項目41に記載のシステム。
(項目47)
上記体液のサンプルは、約50μl未満である、項目41に記載のシステム。
(項目48)
上記反応物質は免疫アッセイ試薬を含む、項目41に記載のシステム。
(項目49)
上記免疫アッセイ試薬は、ポリペプチド糖タンパク質、多糖類、脂質、核酸、およびそれらの組み合わせを検出する、項目48に記載のシステム。
(項目50)
上記免疫アッセイ試薬は、薬物、薬物代謝産物、疾病を示すバイオマーカー、組織特異的マーカー、および細胞または細胞型に対して特異的なバイオマーカーから成る群から選択される要素を検出する、項目48に記載のシステム。
(項目51)
上記複数の検体は、3桁の範囲にわたり検出可能な明確な信号によって識別される、項目41に記載のシステム。
(項目52)
上記検出可能な信号は発光信号である、項目41に記載のシステム。
(項目53)
上記検出可能な信号は化学発光信号である、項目41に記載のシステム。
(項目54)
上記流体デバイスは、上記体液のサンプルを採取するための極微針をさらに備える、項目41に記載のシステム。
(項目55)
上記薬理学的パラメーターは薬物動態パラメーターである、項目41に記載のシステム。
(項目56)
上記薬理学的パラメーターは薬力学的パラメーターである、項目41に記載のシステム。
(項目57)
上記複数の上記検体のうちの少なくとも1つは、薬力学的パラメーターを示すバイオマーカーである、項目41に記載のシステム。
(項目58)
上記複数の上記検体のうちの少なくとも1つは、薬物動態パラメーターを示す上記治療薬または該治療薬の代謝産物である、項目41に記載のシステム。
(項目59)
上記流体デバイスは、上記信号に関するデータを無線伝送器経由で伝達する、項目41に記載のシステム。
(項目60)
上記無線伝送器は携帯電話を備える、項目59に記載のシステム。
(項目61)
治療薬の有効性および/または毒性を評価するために有用な2つ以上の薬理学的パラメーターを測定するための方法であって、
a)該2つ以上の薬理学的パラメーターをプロファイリングするために、該治療薬を投与された被験体からの体液のサンプルを流体デバイスに入れるステップであって、該流体医療デバイスは、
カートリッジであって、少なくとも1つのサンプル収集ユニットと、反応試薬を含むアッセイアセンブリとを備える、ステップと、
b)該流体デバイスを作動させ、該流体デバイス内の該免疫アッセイ試薬を方向づけるステップと、
c)該体液のサンプルを免疫アッセイ試薬と反応させ、該サンプルからの該2つ以上の薬理学的パラメーターの値を示す検出可能な信号を発生するステップと、
d)該体液のサンプルから生成される該検出可能な信号を検出するステップと、
を含む、方法。
(項目62)
上記被験体に伝達される無線信号によって促進される時間間隔で(a)〜(d)の上記ステップを反復するステップをさらに含む、項目61に記載の方法。
(項目63)
上記2つ以上の薬理学的パラメーターは、上記治療薬の有効性および/または毒性を評価するのに有用な薬物動態指標および薬力学指標の両方を含む、項目61に記載の方法。
(項目64)
上記薬理学的パラメーターは薬物動態指標である、項目61に記載の方法。
(項目65)
上記薬理学的パラメーターは薬力学指標である、項目61に記載の方法。
(項目66)
上記薬理学的パラメーターは上記治療薬の濃度によって反映される、項目61に記載の方法。
(項目67)
上記薬理学的パラメーターは上記治療薬の代謝産物の濃度によって反映される、項目61に記載の方法。
(項目68)
上記薬理学的パラメーターは、上記治療薬によって直接的または間接的に作用されるバイオマーカーによって反映される、項目61に記載の方法。
(項目69)
上記薬理学的パラメーターは、上記治療薬に対する副作用を表示するバイオマーカーによって反映される、項目61に記載の方法。
(項目70)
治療薬を伴う医療的処置の患者の薬剤服用順守を自動監視するための方法であって、
a)該患者からの体液のサンプルを提供するステップと、
b)該体液のサンプルを流体デバイスでのアッセイ試薬と反応させ、該医療的処置の薬剤服用順守または薬剤服用不順守を示す検体を検出するステップと、
c)該検体の有無を検出するステップと、
d)該患者または医療実務者に該薬剤服用順守または薬剤服用不順守を通知するステップと、
を含む、方法。
(項目71)
上記流体デバイスは、
サンプル収集ユニットおよびアッセイアセンブリであって、該サンプル収集ユニットは、該体液のサンプルを外部デバイスから伝送されるプロトコルに基づき該アッセイアセンブリ内に含有されている反応物質と反応させ、上記検体の存在を示す検出可能な信号を発生する、サンプル収集ユニットおよびアッセイアセンブリと、
該検出可能な信号を検出するための検出アセンブリを備える読取機アセンブリと、
該検出信号を外部デバイスへ伝送するための通信アセンブリと
を備える、項目70に記載の方法。
(項目72)
上記信号と、上記医療的処置と関連することが知られているプロファイルとを自動的に比較する上記ステップをさらに含み、上記患者が該医療的処置を順守しているか、または順守していないかどうかを決定する、項目71に記載の方法。
(項目73)
上記通知は電子的に伝送される、項目70に記載の方法。
(項目74)
上記通知は無線で伝送される、項目70に記載の方法。
(項目75)
上記通知は携帯端末経由で伝送される、項目70の記載に方法。
(項目76)
上記体液のサンプルは約500μl未満である、項目70に記載の方法。
(項目77)
上記反応物質は免疫アッセイ試薬を含む、項目70に記載の方法。
(項目78)
上記検出可能な信号は発光信号である、項目71に記載の方法。
(項目79)
上記検出可能な信号は化学発光信号である、項目71に記載の方法。
(項目80)
流体デバイスを使用して体液のサンプルを検査するよう患者に警告する方法であって、
a)該流体デバイスで実施される、外部デバイスに位置しているプロトコルを提供するステップであって、該プロトコルは、該患者に関連付けられ、かつ該体液のサンプルを検査する時間および/または日付を含む、ステップと、
b)該サンプルがまだ検査されていなければ、該時間および/または日付で該体液を検査するよう該患者に通知するステップと、
を含む、方法。
(項目81)
上記流体デバイスは、
サンプル収集ユニットおよびアッセイアセンブリであって、該サンプル収集ユニットは、上記体液のサンプルを外部デバイスから伝送されるプロトコルに基づき該アッセイアセンブリ内に含有されている反応物質と反応させ、上記検体の存在を示す検出可能な信号を発生する、サンプル収集ユニットおよびアッセイアセンブリと、
該検出可能な信号を検出するための検出アセンブリを備える読取機アセンブリと、
該検出信号を外部デバイスへ伝送するための通信アセンブリと
を備える、項目80に記載の方法。
(項目82)
上記通知は電子的に伝送される、項目81に記載の方法。
(項目83)
上記通知は無線で伝送される、項目80に記載の方法。
(項目84)
上記通知は携帯端末経由で伝送される、項目80に記載の方法。
(項目85)
上記体液のサンプルは約500μl未満である、項目80に記載の方法。
(項目86)
上記反応物質は免疫アッセイ試薬を含む、項目80に記載の方法。
(項目87)
上記検出可能な信号は発光信号である、項目81に記載の方法。
(項目88)
個人に合わせた医療的処置を提供する際に臨床医を支援するビジネス方法であって、
a)医薬を受け取る個人から少なくとも1つの薬理学的パラメーターを収集するステップであって、体液のサンプルを流体デバイスに含有されている反応物質に与えることにより開始され、それが該個人に提供されて該少なくとも1つの薬理学的パラメーターを示す検出可能な信号を発生する、収集するステップと、
b)該個人のコンピュータ医療記録の補助と該個人の該少なくとも1つの薬理学的パラメーターを相互参照することにより、個人に合わせた医療的処置を提供する際に該臨床医を支援するステップと、
を含む、ビジネス方法。
(項目89)
上記薬理学的パラメーターは薬物動態パラメーターである、項目88に記載のビジネス方法。
(項目90)
上記薬理学的パラメーターは薬力学的パラメーターである、項目88に記載のビジネス方法。
(項目91)
上記反応物質は免疫アッセイ試薬を含む、項目88に記載のビジネス方法。
(項目92)
治療薬の臨床試験を監視するビジネス方法であって、
a)上記臨床試験において複数の時間間隔で被験体から少なくとも1つの薬理学的パラメーターを収集するステップであって、該収集するステップは、それぞれの時間間隔で、該被験体からの体液のサンプルを流体デバイスに含有されている反応物質に与えることにより開始され、該流体デバイスを該被験体に提供し、複数の時間間隔で該少なくとも1つの薬理学的パラメーターの値を示す検出可能な信号を発生する、収集するステップと、
b)該検出された値を該薬理学的パラメーターの所定の閾値と比較するステップと、
c)統計的に重大な相違が該検出された値と該閾値との間に存在する場合は、該臨床試験に関与している臨床医および/または治験依頼者に通知するステップと、
を含む、ビジネス方法。
(項目93)
上記統計的に重大な相違に基づき医療行為を起こすステップをさらに含む、項目92に記載のビジネス方法。
(項目94)
上記医療行為は上記治療薬の用量を調整するステップを伴う、項目93に記載のビジネス方法。
(項目95)
上記臨床試験を継続、修正または終了するステップを伴うビジネス決定を行うステップをさらに含む、項目92に記載のビジネス方法。
(項目96)
上記流体デバイスは、
サンプル収集ユニットおよびアッセイアセンブリであって、該サンプル収集ユニットは、上記体液のサンプルを外部デバイスから伝送されるプロトコルに基づき該アッセイアセンブリ内に含有されている反応物質と反応させ、上記検出可能な信号を発生する、サンプル収集ユニットおよびアッセイアセンブリと、
該検出可能な信号を検出するための検出アセンブリを備える読取機アセンブリと、
該検出信号を外部デバイスへ伝送するための通信アセンブリと
を備える、項目92に記載のビジネス方法。
(項目97)
上記反応物質は免疫アッセイ試薬を含む、項目92に記載のビジネス方法。
(項目98)
治療薬の有効性および/または毒性を実験動物から評価するために有用な薬理学データを獲得するための方法であって、
a)少なくとも1つのサンプル収集ユニットおよびアッセイアセンブリを備える流体デバイスと、該サンプル収集ユニットおよび/または該アッセイアセンブリと流体連通している複数のチャネルとを提供するステップと、
b)約50μl未満の生体液のサンプルを該アッセイアセンブリ内に含有されている反応物質と反応させ、薬理学的パラメーターを示す該サンプル中の最初に収集された検体から生成される検出可能な信号を発生する、ステップと、
c)該検出可能な信号を検出するステップと、
d)同じ実験動物から生体液の第2のサンプルを使用して該反応および検出するステップを反復するステップと、
を含む、方法。
(項目99)
治療薬の有効性および/または毒性を実験動物から評価するのに有用な薬理学データを採取する方法であって、
a)少なくとも1つのサンプル収集ユニット、アッセイアセンブリを備える流体デバイスと、該サンプル収集ユニットおよび/または該アッセイアセンブリと流体連通している複数のチャネルを提供するステップと、
b)生体液のサンプルを、該アッセイアセンブリ内に含有されている反応物質と反応させ、薬理学的パラメーターを示す該サンプル中の最初に収集された検体から生成される検出可能な信号を発生するステップと、
c)該検出可能な信号を検出するステップと、
d)該動物が麻酔を受けていない場合、同じ実験動物から生体液の第2のサンプルを使用して該反応および検出するステップを反復するステップと、
を含む、方法。
(項目100)
上記流体デバイスは、
サンプル収集ユニットおよびアッセイアセンブリであって、該サンプル収集ユニットは、上記体液のサンプルを外部デバイスから伝送されるプロトコルに基づき該アッセイアセンブリ内に含有されている反応物質と反応させ、上記検体の存在を示す上記検出可能な信号を発生する、サンプル収集ユニットおよびアッセイアセンブリと、
該検出可能な信号を検出するための検出アセンブリを備える読取機アセンブリと、
該検出信号を外部デバイスへ伝送するための通信アセンブリと
を備える、項目98または99に記載の方法。
(項目101)
上記流体デバイスは、外部デバイスから伝送されるプロトコルに基づき上記アッセイアセンブリ含有されている上記反応物質を充てる、項目100に記載の方法。
(項目102)
上記プロトコルは外部デバイスから無線で伝送される、項目100に記載の方法。
(項目103)
上記流体デバイスは、上記プロトコルの上記伝送の誘因となるよう適合する該流体デバイスの同一性を与える識別子をさらに備える、項目100に記載の方法。
(項目104)
上記プロトコルは、識別子検出器によって認識可能な上記流体デバイスの上記同一性に依存して変化する、項目100に記載の方法。
(項目105)
上記反応物質は免疫アッセイ試薬を含む、項目100に記載の方法。
(項目106)
上記免疫アッセイ試薬は、ポリペプチド糖タンパク質、多糖類、脂質、核酸、およびそれらの組み合わせを検出する、項目105に記載の方法。
(項目107)
上記免疫アッセイ試薬は、薬物、薬物代謝産物、疾病を示すバイオマーカー、組織特異的マーカー、および細胞または細胞型に対して特異的なバイオマーカーから成る群から選択される要素を検出する、項目105に記載の方法。
(項目108)
上記バイオマーカーは表4に示す要素である、項目105に記載の方法。
(項目109)
上記流体デバイスは複数の検体を検出し、かつ該流体デバイスは該複数の検体のための免疫アッセイ試薬を備える、項目100に記載の方法。
(項目110)
上記複数の検体は、3桁の範囲にわたり検出可能な明確な信号によって識別される、項目100に記載の方法。
(項目111)
上記検出可能な信号は発光信号である、項目100に記載の方法。
(項目112)
上記流体デバイスは、上記体液のサンプルを採取するために極微針をさらに備える、項目100に記載の方法。
(項目113)
上記生体液のサンプルは、約10マイクロリットル未満である、項目100に記載の方法。
(項目114)
上記生体液のサンプルは約5マイクロリットル未満である、項目100に記載の方法。
(項目115)
上記生体液のサンプルは約5マイクロリットルと約10マイクロリットルとの間である、項目100に記載の方法。
(項目116)
上記薬理学データは薬物動態および/または薬力学的パラメーターを含む、項目100に記載の方法。
(項目117)
流体システムを較正する精度を向上させる方法であって、
a)体液を提供するための流体デバイスを備える、被験体からの該体液中の検体を検出するためのシステムを提供するステップであって、該流体デバイスは、較正アセンブリと、該検体の存在を検出するための読取機アセンブリとを有する、ステップと、
b)該流体デバイスに関連する較正曲線の1つ以上のパラメーターを測定するステップと、
c)該1つ以上のパラメーターを該流体デバイスに関連する所定のパラメーターと比較するステップと、
d)該1つ以上のパラメーターおよび該所定のパラメーターの比率によって信号出力を調整するステップと、
を含む、方法。
(項目118)
流体システムの較正を向上させる方法であって、
a)検体の既知量を含むオリジナルのサンプルで第1の信号を測定するステップと、
b)該オリジナルのサンプル中の該検体の既知量を混ぜた後で、第2の信号を測定するステップと、
c)目標値が該検体の該既知量から予想される信号である場合、該目標値に対する該第1および第2の信号との差をプロットするステップと、
d)該目標値と計算された検体値との該差の平方和を最小限にすることによって、パラメーターの最良適合に達するステップと、
を含む、方法。
(項目119)
流体デバイスを用いて体液中の検体のためのアッセイの信頼性を評価する方法であって、a)システムを提供するステップであって、該システムは流体デバイスを備え、該流体デバイスは、被験体からの体液中の検体の存在を検出するために、サンプル収集ユニットおよびアッセイアセンブリと、上記検体の存在を検出するための読取機アセンブリとを備え、該サンプル収集ユニットは、体液のサンプルを該アッセイアセンブリ内に含有されている反応物質と反応させる、ステップと、
b)センサーにより、該システムが通常動作する動作パラメーターにおける変化を検知するステップと、
を含む、方法。
(項目120)
被験体の生体液中の検体を検出するための装置であって、
a)複数の反応部位と流体連通している生体液を導入するためのサンプル収集ユニットと、
b)該反応部位と流体連通している複数の反応物質を運ぶ複数の反応物質チェンバーであって、該複数の反応部位は該検体を検出するためにそこに結合される複数の反応物質を含んでいる、複数の反応物質チェンバーと、
c)該生体液および該複数の反応物質を、該装置に流れさせる流体チャネルのシステムであって、該複数の反応部位の間に位置している少なくとも1つのチャネルは光学バリアを備え、該検体の検出の間に該複数の該反応部位の間の光クロストークの量を軽減するシステムと、
を備える、装置。
(項目121)
被験体の生体液中の検体を検出するための装置であって、
a)複数の反応部位と流体連通している生体液を導入するためのサンプル収集ユニットであって、該複数の反応部位は、該検体を検出するための複数の結合された反応物質を含むサンプル収集ユニットと、
b)該反応部位と流体連通している複数の反応物質を運ぶ複数の反応物質チェンバーと、c)該生体液および該複数の反応物質を該装置に流れさせる流体チャネルのシステムであって、少なくとも1つの反応部位での該結合された反応物質が不規則に分配されるシステムと、
を備える、装置。
(項目122)
被験体の生体液中の検体を検出するための流体デバイスを製造する方法であって、
a)流体デバイスの複数の層を提供するステップと、
b)流体ネットワークがサンプル収集ユニットと、少なくとも1つの反応物質チェンバーと、少なくとも1つの反応部位と、少なくとも1つの廃棄チェンバーとの間に存在するように該層を合わせて超音波溶接するステップと、
を含む、方法。
本明細書に言及するすべての公開および特許出願は、それぞれ個々の公開または特許出願が、参照することによって組み込まれるよう明確に、または個別に表示するとの同じ程度まで、参照することによって本明細書に組み込まれる。
システム
本発明の一側面は、体液のサンプル中の検体を検出するためのシステムである。システムは、特異の生物過程、生理学的状態、疾患または疾患の期に関連する検体を検出および/または定量化することができる。
対象の装置およびシステムは、被験体からの体液中に存在している検体の高処理能力および実時間検出のための有効な手段を提供する。検出方法は、特異の生物過程、生理学的状態、疾患および疾患の期に関連している検体の識別および定量化を含み、多種多様な状況において使用してもよい。そのようなものとして、対象の装置およびシステムは、例えば、薬物スクリーニング、疾病診断、系統発生的分類、母体となる識別、および法医学的識別において広範囲に渡る実用性を有する。対象の装置およびシステムはまた、治療法の開発の前臨床病期および臨床病期を進めるのに、患者の薬剤服用順守を向上させるのに、処方薬に関連するADRを監視するのに、また個人に合わせた医薬を開発するのに特に有用である。
酸カルシウムおよび塩基とともに冷光を発するよう作ることができる。化合物の別の種は、親生成物の一般名称がロフィンである、2,4,5−トリフェニルイミダゾールである。化学発光法による類似物は、パラ−ジメチルアミノおよび−メトキシ置換基を含む。化学発光はまた、シュウ酸塩、通常オキサリル活性エステル、例えば、塩基性条件下で、過酸化水素などのp−ニトロフェニルおよび過酸化物により獲得してもよい。同様に知られている他の有用な化学発光法による化合物は、−N−アルキルアクリジナム(acridinum)エステルおよびジオキセタンを含む。あるいは、ルシフェリンは発光酵素またはルシゲニンと併せて使用し、生体発光をもたらしてもよい。
図24の上端の曲線に示すデータは、それぞれのオリジナルの濃度レベルおよび200pg/ml検体でスパイクされたそれぞれのレベルのための信号における差異に対する較正によって再較正を実施するのに使用した。以下に示す方程式3を経験的に導き、検体のオリジナルの内在性濃度を計算するのに有用である。表2の最良適合パラメーター値は、標的と計算された検体値との差の二乗の合計の最小化によって算出した。濃度=C*((A−D)/((信号−D)^(1/B))+E [方程式3]
(表2:1−ポイント較正のための計算されたパラメーター値)
表3では、×lは内因性濃度であり、×2はスパイク濃度であり、Sは指定された検体濃度に対応する信号レベルであり、×2回復は×2の見掛け回復であり、また×1回復は×2回復(方程式4を使用)を補完した後計算される(方程式5使用)。
サンプルの完全性は、多くの要因によって影響を受けることができ、いくつかは患者に内因性、またいくつは外因性である。以下に記載の、(i)間質液と血液との混合、(ii)ヘマトクリット値濃度におけるばらつき、(iii)溶血反応、および(iv)血小板およびサンプル凝固の活性化は、サンプルの完全性における誤差の原因のうちのいくつかである。
識別子検出器が識別子を検出してプロトコルを決定し、検知されたいかなる信号も検出し、また患者への通知が完了するか、または較正パラメーターが更新された後で、流体デバイスを較正することができ、続いて適切なアッセイを行うことができる。
OPi=(a*IPl+b*IP2+...n*IPn)+(aa*IPl^2+bb*IP2^2+...+nn*IPn^2)+(aaa*IPl*IP2+bbb*IPl*IP3+...+nnn*IPn−l*IPn)、ここでa...n、aa...nn、aaa...nnnは任意定数である。
TI=a*IP+cc*rP3^2+nnn*IP3*IP5+...(方程式6)
図34は、TIの算出結果および治療効力を決定するためのTI概念の使用を例示する(治療指数はまた、項目の効力指数によって表示される)。図34に例示している例は、パラメーターA、BおよびCによって表される3つの生化学的検体によって表示される疾病状態(アテローム性動脈硬化)の成功している薬物療法の経時変化を示す。疾病の治療(例えば、スタチンを使用して)は、ゼロ日に開始している。
Claims (1)
- 本明細書に記載の発明。
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67880105P | 2005-05-09 | 2005-05-09 | |
US60/678,801 | 2005-05-09 | ||
US70548905P | 2005-08-05 | 2005-08-05 | |
US60/705,489 | 2005-08-05 | ||
US71719205P | 2005-09-16 | 2005-09-16 | |
US60/717,192 | 2005-09-16 | ||
US72109705P | 2005-09-28 | 2005-09-28 | |
US60/721,097 | 2005-09-28 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015089977A Division JP2015158506A (ja) | 2005-05-09 | 2015-04-27 | ポイントオブケア流体システムおよびその使用 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019159417A Division JP2019219416A (ja) | 2005-05-09 | 2019-09-02 | ポイントオブケア流体システムおよびその使用 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2017142265A true JP2017142265A (ja) | 2017-08-17 |
Family
ID=37397025
Family Applications (10)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008511111A Withdrawn JP2008544214A (ja) | 2005-05-09 | 2006-03-24 | ポイントオブケア流体システムおよびその使用 |
JP2012081306A Pending JP2012127978A (ja) | 2005-05-09 | 2012-03-30 | ポイントオブケア流体システムおよびその使用 |
JP2012238759A Pending JP2013029525A (ja) | 2005-05-09 | 2012-10-30 | ポイントオブケア流体システムおよびその使用 |
JP2015089977A Withdrawn JP2015158506A (ja) | 2005-05-09 | 2015-04-27 | ポイントオブケア流体システムおよびその使用 |
JP2015089978A Pending JP2015158507A (ja) | 2005-05-09 | 2015-04-27 | ポイントオブケア流体システムおよびその使用 |
JP2017085342A Pending JP2017142265A (ja) | 2005-05-09 | 2017-04-24 | ポイントオブケア流体システムおよびその使用 |
JP2019159417A Pending JP2019219416A (ja) | 2005-05-09 | 2019-09-02 | ポイントオブケア流体システムおよびその使用 |
JP2019163674A Pending JP2019219420A (ja) | 2005-05-09 | 2019-09-09 | ポイントオブケア流体システムおよびその使用 |
JP2021150185A Pending JP2021193390A (ja) | 2005-05-09 | 2021-09-15 | ポイントオブケア流体システムおよびその使用 |
JP2023171310A Pending JP2023169427A (ja) | 2005-05-09 | 2023-10-02 | ポイントオブケア流体システムおよびその使用 |
Family Applications Before (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008511111A Withdrawn JP2008544214A (ja) | 2005-05-09 | 2006-03-24 | ポイントオブケア流体システムおよびその使用 |
JP2012081306A Pending JP2012127978A (ja) | 2005-05-09 | 2012-03-30 | ポイントオブケア流体システムおよびその使用 |
JP2012238759A Pending JP2013029525A (ja) | 2005-05-09 | 2012-10-30 | ポイントオブケア流体システムおよびその使用 |
JP2015089977A Withdrawn JP2015158506A (ja) | 2005-05-09 | 2015-04-27 | ポイントオブケア流体システムおよびその使用 |
JP2015089978A Pending JP2015158507A (ja) | 2005-05-09 | 2015-04-27 | ポイントオブケア流体システムおよびその使用 |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019159417A Pending JP2019219416A (ja) | 2005-05-09 | 2019-09-02 | ポイントオブケア流体システムおよびその使用 |
JP2019163674A Pending JP2019219420A (ja) | 2005-05-09 | 2019-09-09 | ポイントオブケア流体システムおよびその使用 |
JP2021150185A Pending JP2021193390A (ja) | 2005-05-09 | 2021-09-15 | ポイントオブケア流体システムおよびその使用 |
JP2023171310A Pending JP2023169427A (ja) | 2005-05-09 | 2023-10-02 | ポイントオブケア流体システムおよびその使用 |
Country Status (13)
Country | Link |
---|---|
US (20) | US20060264779A1 (ja) |
EP (2) | EP3763824A1 (ja) |
JP (10) | JP2008544214A (ja) |
KR (8) | KR101381331B1 (ja) |
CN (1) | CN101535499B (ja) |
AU (1) | AU2006244617B2 (ja) |
CA (2) | CA2610294C (ja) |
DE (1) | DE20190164T1 (ja) |
ES (1) | ES2820430T3 (ja) |
IL (3) | IL187272A (ja) |
MX (3) | MX2007013985A (ja) |
NZ (6) | NZ599522A (ja) |
WO (1) | WO2006121510A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7423696B2 (ja) | 2017-08-31 | 2024-01-29 | バイオファイア・ダイアグノスティクス,リミテッド・ライアビリティ・カンパニー | アッセイデバイス及びその使用方法 |
Families Citing this family (340)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190357827A1 (en) | 2003-08-01 | 2019-11-28 | Dexcom, Inc. | Analyte sensor |
GB0402131D0 (en) | 2004-01-30 | 2004-03-03 | Isis Innovation | Delivery method |
US7697967B2 (en) | 2005-12-28 | 2010-04-13 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor insertion |
EP3556868A1 (en) | 2005-05-09 | 2019-10-23 | BioFire Diagnostics, LLC | Self-contained biological analysis |
KR101381331B1 (ko) | 2005-05-09 | 2014-04-04 | 테라노스, 인코포레이티드 | 현장진료 유체 시스템 및 그 용도 |
CN102440785A (zh) | 2005-08-31 | 2012-05-09 | 弗吉尼亚大学专利基金委员会 | 传感器信号处理方法及传感器信号处理装置 |
US20070112592A1 (en) | 2005-11-17 | 2007-05-17 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Payments in providing assistance related to health |
US10042980B2 (en) * | 2005-11-17 | 2018-08-07 | Gearbox Llc | Providing assistance related to health |
US20070119928A1 (en) * | 2005-11-17 | 2007-05-31 | Jung Edward K | Generating a nutraceutical request from an inventory |
US8468029B2 (en) * | 2005-11-17 | 2013-06-18 | The Invention Science Fund I, Llc | Subscriptions for assistance related to health |
US8532938B2 (en) | 2005-11-17 | 2013-09-10 | The Invention Science Fund I, Llc | Testing-dependent administration of a nutraceutical |
US20070112589A1 (en) * | 2005-11-17 | 2007-05-17 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | User interface for providing assistance related to health |
US20080179255A1 (en) * | 2007-01-29 | 2008-07-31 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Fluidic devices |
US20080241910A1 (en) * | 2007-03-27 | 2008-10-02 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Devices for pathogen detection |
US20070124219A1 (en) * | 2005-11-30 | 2007-05-31 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational and/or control systems related to individualized nutraceutical selection and packaging |
US20080210748A1 (en) | 2005-11-30 | 2008-09-04 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware, | Systems and methods for receiving pathogen related information and responding |
US20070299693A1 (en) * | 2006-06-23 | 2007-12-27 | Searete Llc, A Limited Liability Corporation | Customized visual marking for medication labeling |
US20080193919A1 (en) * | 2005-11-30 | 2008-08-14 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems and methods for receiving pathogen related information and responding |
US10296720B2 (en) | 2005-11-30 | 2019-05-21 | Gearbox Llc | Computational systems and methods related to nutraceuticals |
US7927787B2 (en) | 2006-06-28 | 2011-04-19 | The Invention Science Fund I, Llc | Methods and systems for analysis of nutraceutical associated components |
US7974856B2 (en) | 2005-11-30 | 2011-07-05 | The Invention Science Fund I, Llc | Computational systems and methods related to nutraceuticals |
US8000981B2 (en) | 2005-11-30 | 2011-08-16 | The Invention Science Fund I, Llc | Methods and systems related to receiving nutraceutical associated information |
US20080178692A1 (en) * | 2007-01-29 | 2008-07-31 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Fluidic methods |
US20080241000A1 (en) * | 2007-03-27 | 2008-10-02 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems for pathogen detection |
US20080082272A1 (en) * | 2005-11-30 | 2008-04-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational systems and methods related to nutraceuticals |
US8340944B2 (en) | 2005-11-30 | 2012-12-25 | The Invention Science Fund I, Llc | Computational and/or control systems and methods related to nutraceutical agent selection and dosing |
US20080033763A1 (en) * | 2005-11-30 | 2008-02-07 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems related to receiving nutraceutical associated information |
US7827042B2 (en) | 2005-11-30 | 2010-11-02 | The Invention Science Fund I, Inc | Methods and systems related to transmission of nutraceutical associated information |
US20080241909A1 (en) * | 2007-03-27 | 2008-10-02 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Microfluidic chips for pathogen detection |
US20080004909A1 (en) * | 2005-11-30 | 2008-01-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational systems related to nutraceuticals |
US8297028B2 (en) | 2006-06-14 | 2012-10-30 | The Invention Science Fund I, Llc | Individualized pharmaceutical selection and packaging |
US20070124175A1 (en) * | 2005-11-30 | 2007-05-31 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware. | Computational and/or control systems and methods related to nutraceutical agent selection and dosing |
US11298058B2 (en) | 2005-12-28 | 2022-04-12 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor insertion |
US7736310B2 (en) | 2006-01-30 | 2010-06-15 | Abbott Diabetes Care Inc. | On-body medical device securement |
US7885698B2 (en) | 2006-02-28 | 2011-02-08 | Abbott Diabetes Care Inc. | Method and system for providing continuous calibration of implantable analyte sensors |
JP5254949B2 (ja) * | 2006-03-15 | 2013-08-07 | マイクロニクス, インコーポレイテッド | 一体型の核酸アッセイ |
US11287421B2 (en) | 2006-03-24 | 2022-03-29 | Labrador Diagnostics Llc | Systems and methods of sample processing and fluid control in a fluidic system |
US8741230B2 (en) | 2006-03-24 | 2014-06-03 | Theranos, Inc. | Systems and methods of sample processing and fluid control in a fluidic system |
US7618369B2 (en) | 2006-10-02 | 2009-11-17 | Abbott Diabetes Care Inc. | Method and system for dynamically updating calibration parameters for an analyte sensor |
US8346335B2 (en) | 2008-03-28 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte sensor calibration management |
US7630748B2 (en) | 2006-10-25 | 2009-12-08 | Abbott Diabetes Care Inc. | Method and system for providing analyte monitoring |
US8374668B1 (en) | 2007-10-23 | 2013-02-12 | Abbott Diabetes Care Inc. | Analyte sensor with lag compensation |
US8219173B2 (en) | 2008-09-30 | 2012-07-10 | Abbott Diabetes Care Inc. | Optimizing analyte sensor calibration |
US8140312B2 (en) | 2007-05-14 | 2012-03-20 | Abbott Diabetes Care Inc. | Method and system for determining analyte levels |
US9339217B2 (en) | 2011-11-25 | 2016-05-17 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods of use |
US8473022B2 (en) | 2008-01-31 | 2013-06-25 | Abbott Diabetes Care Inc. | Analyte sensor with time lag compensation |
US9392969B2 (en) | 2008-08-31 | 2016-07-19 | Abbott Diabetes Care Inc. | Closed loop control and signal attenuation detection |
US9675290B2 (en) | 2012-10-30 | 2017-06-13 | Abbott Diabetes Care Inc. | Sensitivity calibration of in vivo sensors used to measure analyte concentration |
US8224415B2 (en) | 2009-01-29 | 2012-07-17 | Abbott Diabetes Care Inc. | Method and device for providing offset model based calibration for analyte sensor |
US7653425B2 (en) | 2006-08-09 | 2010-01-26 | Abbott Diabetes Care Inc. | Method and system for providing calibration of an analyte sensor in an analyte monitoring system |
US8007999B2 (en) | 2006-05-10 | 2011-08-30 | Theranos, Inc. | Real-time detection of influenza virus |
US8137626B2 (en) | 2006-05-19 | 2012-03-20 | California Institute Of Technology | Fluorescence detector, filter device and related methods |
EP2030025A2 (en) * | 2006-06-07 | 2009-03-04 | Tethys Bioscience, Inc. | Markers associated with arteriovascular events and methods of use thereof |
US20080177149A1 (en) * | 2006-06-16 | 2008-07-24 | Stefan Weinert | System and method for collecting patient information from which diabetes therapy may be determined |
US20070299695A1 (en) * | 2006-06-23 | 2007-12-27 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Customized visual marking for medication labeling |
US20080086338A1 (en) * | 2006-06-23 | 2008-04-10 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Customized visual marking for medication labeling |
US8252160B2 (en) * | 2006-07-28 | 2012-08-28 | Hewlett-Packard Development Company, L.P. | Prevention of fluid delivered to reservoir from wicking into channels within microfluidic device |
US7846110B2 (en) * | 2006-08-03 | 2010-12-07 | Advanced Medical Products Gmbh | Self-contained test unit for testing body fluids |
US20080154530A1 (en) * | 2006-09-01 | 2008-06-26 | Murray David W | Method for normalized test line limits with measurement uncertainty |
US8187541B2 (en) * | 2006-09-18 | 2012-05-29 | California Institute Of Technology | Apparatus for detecting target molecules and related methods |
WO2008060784A2 (en) * | 2006-10-05 | 2008-05-22 | Affinex, Llc | System for rapid analysis of glycated proteinaceous species in biological samples |
SE530596C2 (sv) * | 2006-10-13 | 2008-07-15 | Mathias Karlsson | Metod att fastställa syrebrist i blod från skalpen under förlossning |
US8008034B2 (en) * | 2006-10-13 | 2011-08-30 | Theranos, Inc. | Reducing optical interference in a fluidic device |
US8012744B2 (en) | 2006-10-13 | 2011-09-06 | Theranos, Inc. | Reducing optical interference in a fluidic device |
AU2013267006B2 (en) * | 2006-10-13 | 2015-06-11 | Labrador Diagnostics Llc | Reducing optical interference in a fluidic device |
JP5855332B2 (ja) * | 2006-10-18 | 2016-02-09 | アクセラ インコーポレーテッド | 広い濃度範囲にわたる複数アナライトの光回折による測定 |
US8135548B2 (en) | 2006-10-26 | 2012-03-13 | Abbott Diabetes Care Inc. | Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors |
US20080113391A1 (en) | 2006-11-14 | 2008-05-15 | Ian Gibbons | Detection and quantification of analytes in bodily fluids |
US9102911B2 (en) | 2009-05-15 | 2015-08-11 | Biofire Diagnostics, Llc | High density self-contained biological analysis |
WO2008070618A2 (en) * | 2006-12-01 | 2008-06-12 | Ameritox, Ltd. | Method and apparatus for generating toxicology reports |
US8642093B2 (en) * | 2007-10-30 | 2014-02-04 | The Invention Science Fund I, Llc | Methods and systems for use of photolyzable nitric oxide donors |
US7975699B2 (en) * | 2007-10-30 | 2011-07-12 | The Invention Science Fund I, Llc | Condoms configured to facilitate release of nitric oxide |
US20090110933A1 (en) * | 2007-10-30 | 2009-04-30 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems and devices related to nitric oxide releasing materials |
US20110190604A1 (en) * | 2006-12-22 | 2011-08-04 | Hyde Roderick A | Nitric oxide sensors and systems |
WO2008083323A1 (en) * | 2006-12-29 | 2008-07-10 | Invitrogen Corporation | Detection apparatus |
US20090050569A1 (en) * | 2007-01-29 | 2009-02-26 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Fluidic methods |
US20080245740A1 (en) * | 2007-01-29 | 2008-10-09 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Fluidic methods |
US20090227005A1 (en) * | 2007-03-27 | 2009-09-10 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods for pathogen detection |
ES2784736T3 (es) | 2007-04-14 | 2020-09-30 | Abbott Diabetes Care Inc | Procedimiento y aparato para proporcionar el procesamiento y control de datos en un sistema de comunicación médica |
EP2146625B1 (en) | 2007-04-14 | 2019-08-14 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
EP2146627B1 (en) | 2007-04-14 | 2020-07-29 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
US9204827B2 (en) | 2007-04-14 | 2015-12-08 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
US9125548B2 (en) | 2007-05-14 | 2015-09-08 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8444560B2 (en) | 2007-05-14 | 2013-05-21 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8239166B2 (en) | 2007-05-14 | 2012-08-07 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8260558B2 (en) | 2007-05-14 | 2012-09-04 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8600681B2 (en) | 2007-05-14 | 2013-12-03 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8103471B2 (en) | 2007-05-14 | 2012-01-24 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US10002233B2 (en) | 2007-05-14 | 2018-06-19 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8560038B2 (en) | 2007-05-14 | 2013-10-15 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US9458451B2 (en) | 2007-06-21 | 2016-10-04 | Gen-Probe Incorporated | Multi-channel optical measurement instrument |
US8160900B2 (en) | 2007-06-29 | 2012-04-17 | Abbott Diabetes Care Inc. | Analyte monitoring and management device and method to analyze the frequency of user interaction with the device |
US8834366B2 (en) | 2007-07-31 | 2014-09-16 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor calibration |
US8158430B1 (en) | 2007-08-06 | 2012-04-17 | Theranos, Inc. | Systems and methods of fluidic sample processing |
JP5044334B2 (ja) * | 2007-09-06 | 2012-10-10 | 株式会社ニコン | 採液収容装置 |
EP2195446A4 (en) * | 2007-09-17 | 2011-06-22 | Red Ivory Llc | Self-activating signal-producing detection devices and methods |
CN103323610B (zh) | 2007-10-02 | 2016-12-28 | 赛拉诺斯股份有限公司 | 模块化现场护理装置及其应用 |
JP5628677B2 (ja) | 2007-10-19 | 2014-11-19 | ベクトン・ディキンソン・アンド・カンパニーBecton, Dickinson And Company | ベータ−ラクタマーゼの検出のための方法および組成物 |
US8409093B2 (en) | 2007-10-23 | 2013-04-02 | Abbott Diabetes Care Inc. | Assessing measures of glycemic variability |
US8377031B2 (en) | 2007-10-23 | 2013-02-19 | Abbott Diabetes Care Inc. | Closed loop control system with safety parameters and methods |
US10080823B2 (en) * | 2007-10-30 | 2018-09-25 | Gearbox Llc | Substrates for nitric oxide releasing devices |
US20090112055A1 (en) * | 2007-10-30 | 2009-04-30 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Sleeves configured to facilitate release of nitric oxide |
US8877508B2 (en) | 2007-10-30 | 2014-11-04 | The Invention Science Fund I, Llc | Devices and systems that deliver nitric oxide |
US20110182970A1 (en) * | 2007-10-30 | 2011-07-28 | Hyde Roderick A | Nitric oxide sensors and systems |
US8980332B2 (en) | 2007-10-30 | 2015-03-17 | The Invention Science Fund I, Llc | Methods and systems for use of photolyzable nitric oxide donors |
US8349262B2 (en) * | 2007-10-30 | 2013-01-08 | The Invention Science Fund I, Llc | Nitric oxide permeable housings |
WO2009079589A2 (en) | 2007-12-17 | 2009-06-25 | New World Pharmaceuticals, Llc | Integrated intra-dermal delivery, diagnostic and communication system |
US20090164239A1 (en) | 2007-12-19 | 2009-06-25 | Abbott Diabetes Care, Inc. | Dynamic Display Of Glucose Information |
US9220678B2 (en) | 2007-12-24 | 2015-12-29 | The University Of Queensland | Coating method |
US7766846B2 (en) | 2008-01-28 | 2010-08-03 | Roche Diagnostics Operations, Inc. | Rapid blood expression and sampling |
AU2013202929B2 (en) * | 2008-01-28 | 2016-05-26 | F. Hoffmann-La Roche Ag | System for detection of an analyte in a body fluid |
CN102007066B (zh) | 2008-02-07 | 2013-06-26 | 昆士兰大学 | 贴片制造 |
BRPI0909791A8 (pt) | 2008-03-17 | 2016-08-02 | Koninklije Philips Electronics N V | Cartucho, dispositivo sensor e método para detecção de componentes alvo em uma amostra líquida, e, uso do cartucho ou do dispositivo sensor. |
AU2009250341A1 (en) * | 2008-05-23 | 2009-11-26 | The University Of Queensland | Analyte detection using a needle projection patch |
US8924159B2 (en) | 2008-05-30 | 2014-12-30 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
US8591410B2 (en) | 2008-05-30 | 2013-11-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
US8306594B2 (en) | 2008-06-12 | 2012-11-06 | Paseman Sabrina K | Transmission fluorometer |
JP5401542B2 (ja) * | 2008-06-19 | 2014-01-29 | ベーリンガー インゲルハイム マイクロパーツ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 流体計量容器 |
US20100017092A1 (en) * | 2008-07-16 | 2010-01-21 | Steven Wayne Butler | Hybrid fault isolation system utilizing both model-based and empirical components |
US8734422B2 (en) | 2008-08-31 | 2014-05-27 | Abbott Diabetes Care Inc. | Closed loop control with improved alarm functions |
US20100057040A1 (en) | 2008-08-31 | 2010-03-04 | Abbott Diabetes Care, Inc. | Robust Closed Loop Control And Methods |
US9943644B2 (en) | 2008-08-31 | 2018-04-17 | Abbott Diabetes Care Inc. | Closed loop control with reference measurement and methods thereof |
GB2486842B (en) * | 2008-09-30 | 2013-06-12 | Menai Medical Technologies Ltd | Sample measurement system |
US8986208B2 (en) | 2008-09-30 | 2015-03-24 | Abbott Diabetes Care Inc. | Analyte sensor sensitivity attenuation mitigation |
WO2010047778A1 (en) | 2008-10-20 | 2010-04-29 | Becton Dickinson And Company | Compositions for the detection of intracellular bacterial targets and other intracellular microorganism targets |
US9326707B2 (en) | 2008-11-10 | 2016-05-03 | Abbott Diabetes Care Inc. | Alarm characterization for analyte monitoring devices and systems |
US8643837B2 (en) * | 2009-01-14 | 2014-02-04 | Alverix, Inc. | Methods and materials for calibration of a reader |
JP5086286B2 (ja) * | 2009-01-23 | 2012-11-28 | 株式会社日立ハイテクノロジーズ | 自動分析装置 |
US8103456B2 (en) | 2009-01-29 | 2012-01-24 | Abbott Diabetes Care Inc. | Method and device for early signal attenuation detection using blood glucose measurements |
WO2010091246A2 (en) * | 2009-02-06 | 2010-08-12 | Northwestern University | Burstable liquid packaging and uses thereof |
US9119578B2 (en) | 2011-04-29 | 2015-09-01 | Seventh Sense Biosystems, Inc. | Plasma or serum production and removal of fluids under reduced pressure |
JP6078230B2 (ja) | 2009-03-02 | 2017-02-08 | セブンス センス バイオシステムズ,インコーポレーテッド | 血液サンプリングに関連する技術および装置 |
US9033898B2 (en) | 2010-06-23 | 2015-05-19 | Seventh Sense Biosystems, Inc. | Sampling devices and methods involving relatively little pain |
US9295417B2 (en) | 2011-04-29 | 2016-03-29 | Seventh Sense Biosystems, Inc. | Systems and methods for collecting fluid from a subject |
US9041541B2 (en) | 2010-01-28 | 2015-05-26 | Seventh Sense Biosystems, Inc. | Monitoring or feedback systems and methods |
WO2010121084A1 (en) | 2009-04-15 | 2010-10-21 | Abbott Diabetes Care Inc. | Analyte monitoring system having an alert |
EP2425209A4 (en) | 2009-04-29 | 2013-01-09 | Abbott Diabetes Care Inc | METHOD AND SYSTEM FOR REAL-TIME CALIBRATION OF AN ANALYTICAL SENSOR WITH RETROACTIVE FILLING |
US8790916B2 (en) | 2009-05-14 | 2014-07-29 | Genestream, Inc. | Microfluidic method and system for isolating particles from biological fluid |
GB0911007D0 (en) | 2009-06-25 | 2009-08-12 | Univ Hospital Of North Staffordshire | Analyzer apparatus and methods for lung disease |
ES2776474T3 (es) | 2009-07-23 | 2020-07-30 | Abbott Diabetes Care Inc | Sistema de medición continua de analitos |
EP2456351B1 (en) | 2009-07-23 | 2016-10-12 | Abbott Diabetes Care, Inc. | Real time management of data relating to physiological control of glucose levels |
EP2459994A4 (en) * | 2009-07-27 | 2017-11-22 | Meso Scale Technologies, LLC | Assay information management methods and devices |
WO2011014851A1 (en) | 2009-07-31 | 2011-02-03 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte monitoring system calibration accuracy |
EP3988470B1 (en) | 2009-08-31 | 2023-06-28 | Abbott Diabetes Care Inc. | Displays for a medical device |
US9320461B2 (en) | 2009-09-29 | 2016-04-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing notification function in analyte monitoring systems |
US8518659B2 (en) | 2009-10-14 | 2013-08-27 | Natonal University Corporation Hamamatsu University School of Medicine | Method for determination of degree of risk of onset of high-functioning autism |
US8862448B2 (en) | 2009-10-19 | 2014-10-14 | Theranos, Inc. | Integrated health data capture and analysis system |
US8185181B2 (en) | 2009-10-30 | 2012-05-22 | Abbott Diabetes Care Inc. | Method and apparatus for detecting false hypoglycemic conditions |
EP2502075B1 (en) * | 2009-11-16 | 2015-07-15 | Silicon Biodevices, Inc. | Filtration device for assays |
WO2011062738A1 (en) | 2009-11-23 | 2011-05-26 | Mikhail Briman | Controlled electrochemical activation of carbon-based electrodes |
US11210611B2 (en) | 2011-12-21 | 2021-12-28 | Deka Products Limited Partnership | System, method, and apparatus for electronic patient care |
US10453157B2 (en) | 2010-01-22 | 2019-10-22 | Deka Products Limited Partnership | System, method, and apparatus for electronic patient care |
US11244745B2 (en) | 2010-01-22 | 2022-02-08 | Deka Products Limited Partnership | Computer-implemented method, system, and apparatus for electronic patient care |
US11164672B2 (en) | 2010-01-22 | 2021-11-02 | Deka Products Limited Partnership | System and apparatus for electronic patient care |
US10911515B2 (en) | 2012-05-24 | 2021-02-02 | Deka Products Limited Partnership | System, method, and apparatus for electronic patient care |
US10242159B2 (en) | 2010-01-22 | 2019-03-26 | Deka Products Limited Partnership | System and apparatus for electronic patient care |
US20110313789A1 (en) | 2010-01-22 | 2011-12-22 | Deka Products Limited Partnership | Electronic patient monitoring system |
US11881307B2 (en) | 2012-05-24 | 2024-01-23 | Deka Products Limited Partnership | System, method, and apparatus for electronic patient care |
CA2786569C (en) | 2010-01-29 | 2019-04-09 | Micronics, Inc. | Sample-to-answer microfluidic cartridge |
US8790592B2 (en) | 2010-02-04 | 2014-07-29 | Bio-Rad Laboratories, Inc. | Measuring multi-analyte samples using an in-line flow cell |
CA2789447A1 (en) * | 2010-02-12 | 2011-08-18 | Northwestern University | Assay card for sample acquisition, treatment and reaction |
WO2011112753A1 (en) | 2010-03-10 | 2011-09-15 | Abbott Diabetes Care Inc. | Systems, devices and methods for managing glucose levels |
PL2561368T4 (pl) * | 2010-04-19 | 2018-03-30 | Biomarker Strategies, Llc. | Kompozycje i sposoby do przewidywania wrażliwości i oporności na lek oraz progresji choroby |
US20130143806A1 (en) * | 2010-04-21 | 2013-06-06 | Regents Of The University Of Minnesota | Method for early prognosis of kidney disease |
US10092229B2 (en) | 2010-06-29 | 2018-10-09 | Abbott Diabetes Care Inc. | Calibration of analyte measurement system |
US9943673B2 (en) | 2010-07-14 | 2018-04-17 | Vaxxas Pty Limited | Patch applying apparatus |
US20120016308A1 (en) | 2010-07-16 | 2012-01-19 | Seventh Sense Biosystems, Inc. | Low-pressure packaging for fluid devices |
US20130158482A1 (en) | 2010-07-26 | 2013-06-20 | Seventh Sense Biosystems, Inc. | Rapid delivery and/or receiving of fluids |
WO2012021801A2 (en) | 2010-08-13 | 2012-02-16 | Seventh Sense Biosystems, Inc. | Systems and techniques for monitoring subjects |
EP2603256B1 (en) * | 2010-08-13 | 2015-07-22 | Seventh Sense Biosystems, Inc. | Clinical and/or consumer techniques and devices |
US20120208202A1 (en) * | 2010-09-17 | 2012-08-16 | Alere Scarborough, Inc. | Method for the Reduction of Biological Sampling Errors by Means of Image Processing |
EP2992827B1 (en) | 2010-11-09 | 2017-04-19 | Seventh Sense Biosystems, Inc. | Systems and interfaces for blood sampling |
CN106323876B (zh) | 2011-01-21 | 2020-02-14 | 西拉诺斯知识产权有限责任公司 | 样品使用最大化的系统和方法 |
US10136845B2 (en) | 2011-02-28 | 2018-11-27 | Abbott Diabetes Care Inc. | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
US8506803B2 (en) * | 2011-03-01 | 2013-08-13 | Wisconsin Alumni Research Foundation | Integrated electrospray ionization emitter and detection cell for parallel measurements by fluorescence and mass spectrometry |
ES2799422T3 (es) | 2011-03-10 | 2020-12-17 | General Atomics | Dispositivos y métodos de diagnóstico y preparación de muestras |
US20120229808A1 (en) * | 2011-03-11 | 2012-09-13 | Electronics And Telecommunications Research Institute | Biochip identification apparatus, biochip and method of identifying biochip using the same |
WO2012142502A2 (en) | 2011-04-15 | 2012-10-18 | Dexcom Inc. | Advanced analyte sensor calibration and error detection |
EP2527814A1 (en) * | 2011-04-27 | 2012-11-28 | Koninklijke Philips Electronics N.V. | Sensor system with an exchangeable cartridge and a reader |
EP2701600B1 (en) | 2011-04-29 | 2016-06-08 | Seventh Sense Biosystems, Inc. | Delivering and/or receiving fluids |
US20130158468A1 (en) | 2011-12-19 | 2013-06-20 | Seventh Sense Biosystems, Inc. | Delivering and/or receiving material with respect to a subject surface |
CN104160274A (zh) * | 2011-05-30 | 2014-11-19 | 奥德特里克公司 | 通过照护点药物动力学曲线分析进行治疗药物监测和投配的方法与组合物 |
US8606595B2 (en) | 2011-06-17 | 2013-12-10 | Sanjay Udani | Methods and systems for assuring compliance |
US8655796B2 (en) | 2011-06-17 | 2014-02-18 | Sanjay Udani | Methods and systems for recording verifiable documentation |
US8653715B1 (en) | 2011-06-30 | 2014-02-18 | The United States Of America As Represented By The Secretary Of The Navy | Radioisotope-powered energy source |
EP2737315B1 (en) | 2011-07-25 | 2022-03-16 | Proxim Diagnostics Corporation | Cartridge for diagnostic testing |
US9619627B2 (en) | 2011-09-25 | 2017-04-11 | Theranos, Inc. | Systems and methods for collecting and transmitting assay results |
US8435738B2 (en) | 2011-09-25 | 2013-05-07 | Theranos, Inc. | Systems and methods for multi-analysis |
US9632102B2 (en) | 2011-09-25 | 2017-04-25 | Theranos, Inc. | Systems and methods for multi-purpose analysis |
US9664702B2 (en) | 2011-09-25 | 2017-05-30 | Theranos, Inc. | Fluid handling apparatus and configurations |
US8475739B2 (en) | 2011-09-25 | 2013-07-02 | Theranos, Inc. | Systems and methods for fluid handling |
US9268915B2 (en) | 2011-09-25 | 2016-02-23 | Theranos, Inc. | Systems and methods for diagnosis or treatment |
US20140170735A1 (en) | 2011-09-25 | 2014-06-19 | Elizabeth A. Holmes | Systems and methods for multi-analysis |
US8840838B2 (en) | 2011-09-25 | 2014-09-23 | Theranos, Inc. | Centrifuge configurations |
US9810704B2 (en) | 2013-02-18 | 2017-11-07 | Theranos, Inc. | Systems and methods for multi-analysis |
US9250229B2 (en) | 2011-09-25 | 2016-02-02 | Theranos, Inc. | Systems and methods for multi-analysis |
SG10201602141QA (en) * | 2011-09-25 | 2016-04-28 | Theranos Inc | Systems And Methods For Multi-Analysis |
US10012664B2 (en) | 2011-09-25 | 2018-07-03 | Theranos Ip Company, Llc | Systems and methods for fluid and component handling |
WO2013053022A1 (en) | 2011-10-12 | 2013-04-18 | The University Of Queensland | Delivery device |
US9622691B2 (en) | 2011-10-31 | 2017-04-18 | Abbott Diabetes Care Inc. | Model based variable risk false glucose threshold alarm prevention mechanism |
TWI457562B (zh) | 2011-11-22 | 2014-10-21 | Wistron Corp | 流式細胞儀及生物晶片檢測方法 |
US9317656B2 (en) | 2011-11-23 | 2016-04-19 | Abbott Diabetes Care Inc. | Compatibility mechanisms for devices in a continuous analyte monitoring system and methods thereof |
US8710993B2 (en) | 2011-11-23 | 2014-04-29 | Abbott Diabetes Care Inc. | Mitigating single point failure of devices in an analyte monitoring system and methods thereof |
US20140323347A1 (en) | 2011-11-28 | 2014-10-30 | Tracker Llc | Point of care immunization testing system |
US10449537B2 (en) * | 2011-12-15 | 2019-10-22 | Dna Medicine Institute, Inc. | Capillary manipulation of clinical samples |
US20150055132A1 (en) * | 2012-04-05 | 2015-02-26 | Renishaw Diagnostics Limited | Method for calibrating spectroscopy apparatus and equipment for use in the method |
US9081001B2 (en) | 2012-05-15 | 2015-07-14 | Wellstat Diagnostics, Llc | Diagnostic systems and instruments |
US9213043B2 (en) | 2012-05-15 | 2015-12-15 | Wellstat Diagnostics, Llc | Clinical diagnostic system including instrument and cartridge |
US9625465B2 (en) | 2012-05-15 | 2017-04-18 | Defined Diagnostics, Llc | Clinical diagnostic systems |
US9500639B2 (en) | 2012-07-18 | 2016-11-22 | Theranos, Inc. | Low-volume coagulation assay |
SG11201500347SA (en) | 2012-07-25 | 2015-02-27 | Theranos Inc | Image analysis and measurement of biological samples |
EP2890297B1 (en) | 2012-08-30 | 2018-04-11 | Abbott Diabetes Care, Inc. | Dropout detection in continuous analyte monitoring data during data excursions |
WO2014034781A1 (ja) * | 2012-08-31 | 2014-03-06 | 国立大学法人東京大学 | 検出装置及び検出方法 |
GB2505706A (en) * | 2012-09-10 | 2014-03-12 | Univ Leiden | Apparatus comprising meniscus alignment barriers |
MX2015002919A (es) | 2012-09-11 | 2015-08-14 | Theranos Inc | Sistemas y metodos de manejo de informacion que utilizan una firma biologica. |
WO2014052136A1 (en) * | 2012-09-26 | 2014-04-03 | Abbott Diabetes Care Inc. | Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data |
US20140114676A1 (en) | 2012-10-23 | 2014-04-24 | Theranos, Inc. | Drug Monitoring and Regulation Systems and Methods |
US20140322706A1 (en) * | 2012-10-24 | 2014-10-30 | Jon Faiz Kayyem | Integrated multipelx target analysis |
JP1628115S (ja) | 2012-10-24 | 2019-04-01 | ||
RU2015121732A (ru) | 2012-11-15 | 2017-01-10 | Орто-Клиникал Дайэгностикс, Инк. | Калибровка анализов с использованием времени реакции |
WO2014083667A1 (ja) * | 2012-11-29 | 2014-06-05 | ミライアル株式会社 | サンドイッチ法による抗原抗体反応測定方法 |
EP2932266A4 (en) | 2012-12-17 | 2016-11-30 | Leukodx Ltd | SYSTEMS AND METHODS FOR DETERMINING A CHEMICAL STATE |
US10610861B2 (en) | 2012-12-17 | 2020-04-07 | Accellix Ltd. | Systems, compositions and methods for detecting a biological condition |
US20150346097A1 (en) | 2012-12-21 | 2015-12-03 | Micronics, Inc. | Portable fluorescence detection system and microassay cartridge |
WO2014100743A2 (en) | 2012-12-21 | 2014-06-26 | Micronics, Inc. | Low elasticity films for microfluidic use |
CN104919191B (zh) | 2012-12-21 | 2019-07-09 | 精密公司 | 流体回路及相关的制造方法 |
US9805407B2 (en) | 2013-01-25 | 2017-10-31 | Illumina, Inc. | Methods and systems for using a cloud computing environment to configure and sell a biological sample preparation cartridge and share related data |
EP4220120A3 (en) | 2013-02-18 | 2024-01-10 | Labrador Diagnostics LLC | Systems and methods for multi-analysis |
CN105264358A (zh) | 2013-02-18 | 2016-01-20 | 赛拉诺斯股份有限公司 | 生物样品的图像分析及测量 |
US11008628B1 (en) * | 2013-02-18 | 2021-05-18 | Labrador Diagnostics Llc | Systems and methods for analyte testing and laboratory oversight |
CN109813923A (zh) * | 2013-02-18 | 2019-05-28 | 赛拉诺斯知识产权有限责任公司 | 用于采集和传输测定结果的系统和方法 |
US10401373B1 (en) | 2013-02-18 | 2019-09-03 | Theranos Ip Company, Llc | Systems and methods for analyte testing and laboratory oversight |
EP3595246A1 (en) | 2013-03-04 | 2020-01-15 | Theranos IP Company, LLC | Network connectivity methods and systems |
US10545161B2 (en) | 2013-03-11 | 2020-01-28 | Cue Health Inc. | Systems and methods for detection and quantification of analytes |
CA3160098A1 (en) | 2013-03-11 | 2014-10-09 | Cue Health Inc. | Systems and methods for detection and quantification of analytes |
US9623409B2 (en) | 2013-03-11 | 2017-04-18 | Cue Inc. | Cartridges, kits, and methods for enhanced mixing for detection and quantification of analytes |
WO2014159333A1 (en) * | 2013-03-14 | 2014-10-02 | Bayer Healthcare Llc | System error compensation of analyte concentration determinations |
WO2014159354A1 (en) * | 2013-03-14 | 2014-10-02 | Bayer Healthcare Llc | Progressive approximation of sample analyte concentration |
US10433773B1 (en) | 2013-03-15 | 2019-10-08 | Abbott Diabetes Care Inc. | Noise rejection methods and apparatus for sparsely sampled analyte sensor data |
EP3520895A1 (en) | 2013-03-15 | 2019-08-07 | Genmark Diagnostics Inc. | Fluid container with cantilevered lance |
US9458488B2 (en) | 2013-03-15 | 2016-10-04 | Nanomix, Inc. | Point of care sensor systems |
US9474475B1 (en) | 2013-03-15 | 2016-10-25 | Abbott Diabetes Care Inc. | Multi-rate analyte sensor data collection with sample rate configurable signal processing |
US10076285B2 (en) | 2013-03-15 | 2018-09-18 | Abbott Diabetes Care Inc. | Sensor fault detection using analyte sensor data pattern comparison |
US10386377B2 (en) | 2013-05-07 | 2019-08-20 | Micronics, Inc. | Microfluidic devices and methods for performing serum separation and blood cross-matching |
EP2994543B1 (en) | 2013-05-07 | 2018-08-15 | Micronics, Inc. | Device for preparation and analysis of nucleic acids |
CA2911303C (en) | 2013-05-07 | 2021-02-16 | Micronics, Inc. | Methods for preparation of nucleic acid-containing samples using clay minerals and alkaline solutions |
JP6034238B2 (ja) * | 2013-05-17 | 2016-11-30 | 日本電信電話株式会社 | 血液凝固検査方法 |
EP3014262B1 (en) * | 2013-06-17 | 2023-08-09 | Waters Technologies Corporation | Compensation for chromatography column volume variations |
WO2015006503A1 (en) * | 2013-07-09 | 2015-01-15 | Smith Lucas David | Device and method of rapid linker mediated label-based immunoassays |
US10422806B1 (en) | 2013-07-25 | 2019-09-24 | Theranos Ip Company, Llc | Methods for improving assays of biological samples |
CN105849277A (zh) * | 2013-08-07 | 2016-08-10 | 艾克泽基因公司 | 用于在诊断装置中配置机载试剂的系统、装置和方法 |
US10082500B2 (en) * | 2013-08-22 | 2018-09-25 | Franz Baudenbacher | Device and method for detecting a target analyte |
CN111378568A (zh) * | 2013-09-06 | 2020-07-07 | 赛拉诺斯知识产权有限责任公司 | 用于检测感染性疾病的系统和方法 |
US10943689B1 (en) | 2013-09-06 | 2021-03-09 | Labrador Diagnostics Llc | Systems and methods for laboratory testing and result management |
MX2016002797A (es) | 2013-09-06 | 2016-05-26 | Theranos Inc | Dispositivos, sistemas, metodos y equipos para recibir un hisopo. |
US11545241B1 (en) | 2013-09-07 | 2023-01-03 | Labrador Diagnostics Llc | Systems and methods for analyte testing and data management |
US9498778B2 (en) | 2014-11-11 | 2016-11-22 | Genmark Diagnostics, Inc. | Instrument for processing cartridge for performing assays in a closed sample preparation and reaction system |
USD881409S1 (en) | 2013-10-24 | 2020-04-14 | Genmark Diagnostics, Inc. | Biochip cartridge |
US11229382B2 (en) | 2013-12-31 | 2022-01-25 | Abbott Diabetes Care Inc. | Self-powered analyte sensor and devices using the same |
GB201401426D0 (en) * | 2014-01-28 | 2014-03-12 | Univ Strathclyde | Automated Assay |
US11360107B1 (en) | 2014-02-25 | 2022-06-14 | Labrador Diagnostics Llc | Systems and methods for sample handling |
WO2015136060A1 (en) * | 2014-03-12 | 2015-09-17 | Ge Healthcare Bio-Sciences Ab | Automatic gas valve container holder for chemical synthesis |
US20170185748A1 (en) | 2014-03-30 | 2017-06-29 | Abbott Diabetes Care Inc. | Method and Apparatus for Determining Meal Start and Peak Events in Analyte Monitoring Systems |
AU2015247338B2 (en) | 2014-04-17 | 2020-10-08 | Z-Integrated Digital Technologies, Inc. | Electronic test device data communication |
USD745423S1 (en) | 2014-05-12 | 2015-12-15 | Cue Inc. | Automated analyzer test cartridge and sample collection device for analyte detection |
US9987427B1 (en) * | 2014-06-24 | 2018-06-05 | National Technology & Engineering Solutions Of Sandia, Llc | Diagnostic/drug delivery “sense-respond” devices, systems, and uses thereof |
EP3161483A4 (en) * | 2014-06-25 | 2017-12-20 | ImmunoProfile, LLC | Point of care immunization testing system - detection methods |
WO2016007886A1 (en) | 2014-07-11 | 2016-01-14 | Northwestern University | Yeast-based biosensor |
CA2958871C (en) | 2014-08-22 | 2023-10-03 | Jaywant P. PARMAR | Advanced electromagnetic motion and tracking peripherally inserted central venous catheter system with extended endovascular applications |
EP2995937A1 (en) * | 2014-09-15 | 2016-03-16 | Sensirion AG | Integrated chemical sensor chip |
US10114031B2 (en) | 2014-09-26 | 2018-10-30 | Abbott Point Of Care Inc. | Single channel cartridge device for coagulation assays in fluid samples |
WO2016049533A1 (en) | 2014-09-26 | 2016-03-31 | Abbott Point Of Care Inc. | Cartridge device with fluidic junctions for coagulation assays in fluid samples |
CN106999930B (zh) | 2014-09-26 | 2020-09-08 | 雅培医护站股份有限公司 | 用于测定流体样本中的凝结的具有分段射流的盒设备 |
WO2016049557A1 (en) | 2014-09-26 | 2016-03-31 | Abbott Point Of Care Inc. | Ellagic acid formulations for use in coagulation assays |
WO2016049552A1 (en) | 2014-09-26 | 2016-03-31 | Abbott Point Of Care Inc. | Cartridge device identification for coagulation assays in fluid samples |
EP3955003B1 (en) | 2014-09-26 | 2023-06-21 | Abbott Point Of Care Inc | Sensors for assaying coagulation in fluid samples |
EP3954457A3 (en) | 2014-09-26 | 2022-05-18 | Abbott Point Of Care Inc | Microfabricated device with micro-environment sensors for assaying coagulation in fluid samples |
US9506908B2 (en) | 2014-10-06 | 2016-11-29 | Alveo Technologies, Inc. | System for detection of analytes |
US10627358B2 (en) | 2014-10-06 | 2020-04-21 | Alveo Technologies, Inc. | Method for detection of analytes |
US10352899B2 (en) | 2014-10-06 | 2019-07-16 | ALVEO Technologies Inc. | System and method for detection of silver |
US9921182B2 (en) | 2014-10-06 | 2018-03-20 | ALVEO Technologies Inc. | System and method for detection of mercury |
US10196678B2 (en) | 2014-10-06 | 2019-02-05 | ALVEO Technologies Inc. | System and method for detection of nucleic acids |
EP3204773A4 (en) | 2014-10-08 | 2018-10-10 | Theranos, Inc. | Methods and devices for real-time diagnostic testing (rdt) for ebola and other infectious diseases |
US10005080B2 (en) | 2014-11-11 | 2018-06-26 | Genmark Diagnostics, Inc. | Instrument and cartridge for performing assays in a closed sample preparation and reaction system employing electrowetting fluid manipulation |
WO2016087957A1 (en) * | 2014-12-05 | 2016-06-09 | Diasys Diagnostics India Private Limited | Multiplexed microfluidic device |
JP6613026B2 (ja) * | 2014-12-22 | 2019-11-27 | 日精株式会社 | 採血具 |
WO2016123163A2 (en) | 2015-01-27 | 2016-08-04 | Kardiatonos, Inc. | Biomarkers of vascular disease |
CA2975275C (en) | 2015-02-02 | 2023-08-29 | Vaxxas Pty Limited | Microprojection array applicator and method |
WO2016134217A1 (en) * | 2015-02-19 | 2016-08-25 | Surface Sensing Technologies Llc | Device and method for detecting a target analyte |
EP3290928A4 (en) * | 2015-04-30 | 2018-10-10 | Sysmex Corporation | Liquid encapsulation cartridge, sample analysis device, and sample analysis method |
EP3319518A4 (en) | 2015-07-10 | 2019-03-13 | Abbott Diabetes Care Inc. | SYSTEM, DEVICE AND METHOD FOR DYNAMIC GLUCOSE PROFILE RESPONSE TO PHYSIOLOGICAL PARAMETERS |
CN112881730A (zh) | 2015-07-17 | 2021-06-01 | 克忧健康公司 | 用于增强检测和分析物定量的系统及方法 |
CN108463244B (zh) | 2015-08-04 | 2022-05-27 | 杜克大学 | 用于递送的基因编码的固有无序隐形聚合物及其使用方法 |
WO2017045031A1 (en) | 2015-09-18 | 2017-03-23 | Vaxxas Pty Limited | Microprojection arrays with microprojections having large surface area profiles |
US11752213B2 (en) | 2015-12-21 | 2023-09-12 | Duke University | Surfaces having reduced non-specific binding and antigenicity |
US10088494B2 (en) * | 2016-01-25 | 2018-10-02 | Perkinelmer Health Sciences, Inc. | Method and system for microfluidic sample analysis |
WO2017164982A1 (en) * | 2016-03-21 | 2017-09-28 | The Regents Of The University Of California | Real-time and continuous measurement in vivo using aptamer-based biosensors |
US9892225B2 (en) * | 2016-04-01 | 2018-02-13 | International Business Machines Corporation | Method for optimizing the design of micro-fluidic devices |
US11467156B2 (en) | 2016-06-01 | 2022-10-11 | Duke University | Nonfouling biosensors |
US10989724B1 (en) | 2016-07-29 | 2021-04-27 | Labrador Diagnostics Llc | Systems and methods for multi-analysis |
WO2018057647A1 (en) | 2016-09-23 | 2018-03-29 | Alveo Technologies, Inc. | Methods and compositions for detecting analytes |
AU2017338680A1 (en) | 2016-10-07 | 2019-05-16 | Boehringer Ingelheim Vetmedica Gmbh | Analysis system and method for testing a sample |
US10346653B2 (en) * | 2016-10-07 | 2019-07-09 | Boehringer Ingelheim Vetmedica Gmbh | Cartridge and analysis system for testing a sample |
US10258741B2 (en) | 2016-12-28 | 2019-04-16 | Cequr Sa | Microfluidic flow restrictor and system |
WO2018132732A1 (en) | 2017-01-12 | 2018-07-19 | Duke University | Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly |
WO2018140540A1 (en) | 2017-01-25 | 2018-08-02 | Cue Health Inc. | Systems and methods for enhanced detection and quantification of analytes |
US11213819B2 (en) * | 2017-01-30 | 2022-01-04 | Noavaran Payesh Ani Salamat (AZSense) | Integrated patient monitor system |
US10600337B2 (en) | 2017-01-31 | 2020-03-24 | Bank Of America Corporation | Intelligent content parsing with synthetic speech and tangible braille production |
US11596330B2 (en) | 2017-03-21 | 2023-03-07 | Abbott Diabetes Care Inc. | Methods, devices and system for providing diabetic condition diagnosis and therapy |
CN110709250B (zh) | 2017-03-31 | 2022-10-11 | 瓦克萨斯私人有限公司 | 用于涂覆表面的设备和方法 |
US20180292380A1 (en) * | 2017-04-07 | 2018-10-11 | Lifehealth, Llc | Multi-liquid quality calibration single-use cartridge |
CA3059399C (en) | 2017-04-07 | 2024-01-02 | Easydx, Inc. | Point of care test cartridge |
US11554097B2 (en) | 2017-05-15 | 2023-01-17 | Duke University | Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents |
EP3639010A4 (en) | 2017-06-13 | 2021-03-17 | Vaxxas Pty Limited | QUALITY CONTROL OF SUBSTRATE COATINGS |
EP3658168A4 (en) | 2017-06-30 | 2021-07-14 | Duke University | ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-RESPONDING BIOPOLYMER NETWORKS |
KR102005493B1 (ko) * | 2017-08-03 | 2019-10-08 | 한국전자통신연구원 | 얼굴 표정 교정 장치 및 이를 사용한 바이오 물질 분석 방법 |
AU2018309562A1 (en) | 2017-08-04 | 2020-02-20 | Vaxxas Pty Limited | Compact high mechanical energy storage and low trigger force actuator for the delivery of microprojection array patches (MAP) |
EP3459632A1 (en) * | 2017-09-26 | 2019-03-27 | Lunaphore Technologies SA | Microfluidic cartrige with built-in sampling device |
US11331022B2 (en) | 2017-10-24 | 2022-05-17 | Dexcom, Inc. | Pre-connected analyte sensors |
US11382540B2 (en) | 2017-10-24 | 2022-07-12 | Dexcom, Inc. | Pre-connected analyte sensors |
US11733323B2 (en) * | 2018-06-13 | 2023-08-22 | Centrul International De Biodinamica | Systems and methods for measuring cellular response to target analytes by controlled application of an oscillating stimulus |
EP3829622A4 (en) | 2018-08-02 | 2022-05-11 | Duke University | DUAL AGONIST FUSION PROTEINS |
CA3114860A1 (en) | 2018-10-02 | 2020-04-09 | WearOptimo Pty Ltd | Electrode arrangement for performing measurements on a biological subject |
CA3114763A1 (en) | 2018-10-02 | 2020-04-09 | WearOptimo Pty Ltd | System for performing measurements on a biological subject |
WO2020180553A1 (en) * | 2019-03-04 | 2020-09-10 | Siemens Healthcare Diagnostics Inc. | Dried reagent polysaccharide surface area stabilization |
US20220205883A1 (en) * | 2019-03-18 | 2022-06-30 | Siemens Healthcare Diagnostics Inc. | Diagnostic consumables incorporating coated micro-projection arrays, and methods thereof |
US11512314B2 (en) | 2019-07-12 | 2022-11-29 | Duke University | Amphiphilic polynucleotides |
CN110736540B (zh) * | 2019-09-18 | 2021-06-22 | 中国科学院合肥物质科学研究院 | 一种266nm泵浦的相关光子自校准太阳光谱辐照度仪 |
US20220338744A1 (en) | 2019-09-27 | 2022-10-27 | Cardiorenal | Overall loop system |
BR112022012054A2 (pt) * | 2019-12-20 | 2022-08-30 | Nutrasource Pharmaceutical And Nutraceutical Services Inc | Métodos e dispositivos microfluídicos para quantificar ácidos graxos, um mediador de pró-resolução especializado ou um metabólito de ácido graxo em uma amostra de fluido |
US20230051263A1 (en) * | 2020-01-09 | 2023-02-16 | The Regents Of The University Of Michigan | Device for rapid and quantitative detection of drugs of abuse in sweat |
TWI758797B (zh) * | 2020-07-28 | 2022-03-21 | 長庚大學 | 應用於生物表面檢測之裝置及方法 |
KR102474238B1 (ko) * | 2020-09-14 | 2022-12-06 | (주) 비비비 | 생체시료 분석용 카트리지 및 이를 이용한 생체시료 분석 시스템 |
WO2022109390A1 (en) * | 2020-11-22 | 2022-05-27 | Gattaco Inc. | Sample transfer devices, and components and methods thereof |
EP4016068A1 (en) * | 2020-12-21 | 2022-06-22 | F. Hoffmann-La Roche AG | Sensor assembly |
TW202305366A (zh) * | 2021-03-23 | 2023-02-01 | 美商健生生物科技公司 | 用於生物反應器醣化物種製造之多參數材料、方法及系統 |
WO2022212162A1 (en) * | 2021-03-31 | 2022-10-06 | Haemonetics Corporation | Hemostasis measurement device quality control formulations |
WO2022221618A1 (en) * | 2021-04-16 | 2022-10-20 | New York University | Bone marrow on a chip |
CN117769650A (zh) * | 2021-07-01 | 2024-03-26 | 蓝鸟生物公司 | 方法 |
GB2622645A (en) * | 2022-09-26 | 2024-03-27 | Tachmed Holdings Ltd | System |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002511965A (ja) * | 1997-07-14 | 2002-04-16 | アボツト・ラボラトリーズ | 遠隔医療 |
JP2002538440A (ja) * | 1999-02-26 | 2002-11-12 | ジェネラル・スキャンニング・インコーポレイテッド | マイクロアレイバイオチップの自動イメージング及び分析 |
JP2003504618A (ja) * | 1999-07-12 | 2003-02-04 | カリパー・テクノロジーズ・コープ. | 化学分析および生化学分析での使用のための光源出力の変調 |
JP2003166910A (ja) * | 2001-11-30 | 2003-06-13 | Asahi Kasei Corp | 送液機構及び該送液機構を備える分析装置 |
JP2004527825A (ja) * | 2001-02-15 | 2004-09-09 | シーメンス アクチエンゲゼルシヤフト | バイオチップ測定装置で得たデータを評価するためのネットワーク |
US20040228766A1 (en) * | 2003-05-14 | 2004-11-18 | Witty Thomas R. | Point of care diagnostic platform |
WO2005024437A1 (ja) * | 2003-09-05 | 2005-03-17 | Nec Corporation | 測定システム |
Family Cites Families (454)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4022A (en) * | 1845-05-01 | Improvement in machines for hackling and cleaning hemp and flax | ||
US2842787A (en) * | 1955-10-24 | 1958-07-15 | Maglin Inc | Loading ramp |
JPS5036087A (ja) | 1973-07-13 | 1975-04-04 | ||
US4003379A (en) * | 1974-04-23 | 1977-01-18 | Ellinwood Jr Everett H | Apparatus and method for implanted self-powered medication dispensing |
US4146029A (en) * | 1974-04-23 | 1979-03-27 | Ellinwood Jr Everett H | Self-powered implanted programmable medication system and method |
US4347176A (en) * | 1980-04-14 | 1982-08-31 | Burroughs Wellcome Co. | Compounds and methods of making same |
FR2498331A1 (fr) | 1981-01-20 | 1982-07-23 | Kadouche Jean | Recipient reactif pour analyse notamment immunologique |
GB8422876D0 (en) | 1984-09-11 | 1984-10-17 | Secr Defence | Silicon implant devices |
US4920213A (en) * | 1985-06-20 | 1990-04-24 | Biotechnology Research Partners, Ltd. | Method and compositions useful in preventing equine influenza |
US5204525A (en) * | 1985-08-05 | 1993-04-20 | Biotrack | Capillary flow device |
JPS6247555A (ja) | 1985-08-23 | 1987-03-02 | エフ.ホフマン ― ラ ロシュ アーゲー | シンチレ−シヨン近接定量法 |
US4731726A (en) * | 1986-05-19 | 1988-03-15 | Healthware Corporation | Patient-operated glucose monitor and diabetes management system |
US4935346A (en) * | 1986-08-13 | 1990-06-19 | Lifescan, Inc. | Minimum procedure system for the determination of analytes |
US5310652A (en) | 1986-08-22 | 1994-05-10 | Hoffman-La Roche Inc. | Reverse transcription with thermostable DNA polymerase-high temperature reverse transcription |
US5322770A (en) | 1989-12-22 | 1994-06-21 | Hoffman-Laroche Inc. | Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription |
US4902969A (en) * | 1987-06-01 | 1990-02-20 | Reliability Incorporated | Automated burn-in system |
US4946795A (en) | 1987-08-27 | 1990-08-07 | Biotrack, Inc. | Apparatus and method for dilution and mixing of liquid samples |
US4910131A (en) * | 1987-12-23 | 1990-03-20 | Mellman Ira S | Idiotype and anti-idiotype antibodies useful in virus detection |
US5162237A (en) | 1988-04-11 | 1992-11-10 | Miles Inc. | Reaction cassette for preforming sequential analytical assays by noncentrifugal and noncapillary manipulations |
US5130238A (en) | 1988-06-24 | 1992-07-14 | Cangene Corporation | Enhanced nucleic acid amplification process |
US5132086A (en) | 1990-02-06 | 1992-07-21 | Chemtrak Corporation | Non-instrumented cholesterol assay |
US5104813A (en) | 1989-04-13 | 1992-04-14 | Biotrack, Inc. | Dilution and mixing cartridge |
US5039617A (en) * | 1989-04-20 | 1991-08-13 | Biotrack, Inc. | Capillary flow device and method for measuring activated partial thromboplastin time |
WO1990013668A1 (en) | 1989-05-05 | 1990-11-15 | Lifecodes Corporation | Method for genetic analysis of a nucleic acid sample |
US5504007A (en) | 1989-05-19 | 1996-04-02 | Becton, Dickinson And Company | Rapid thermal cycle apparatus |
DK0408295T3 (da) | 1989-07-11 | 1996-09-16 | Gen Probe Inc | Fremgangsmåder til opformering af nukleinsyresekvenser |
CA2020958C (en) | 1989-07-11 | 2005-01-11 | Daniel L. Kacian | Nucleic acid sequence amplification methods |
US5089229A (en) * | 1989-11-22 | 1992-02-18 | Vettest S.A. | Chemical analyzer |
US6176962B1 (en) * | 1990-02-28 | 2001-01-23 | Aclara Biosciences, Inc. | Methods for fabricating enclosed microchannel structures |
US5242606A (en) | 1990-06-04 | 1993-09-07 | Abaxis, Incorporated | Sample metering port for analytical rotor having overflow chamber |
US5173193A (en) | 1991-04-01 | 1992-12-22 | Schembri Carol T | Centrifugal rotor having flow partition |
US5061381A (en) | 1990-06-04 | 1991-10-29 | Abaxis, Inc. | Apparatus and method for separating cells from biological fluids |
US5122284A (en) | 1990-06-04 | 1992-06-16 | Abaxis, Inc. | Apparatus and method for optically analyzing biological fluids |
US5527670A (en) | 1990-09-12 | 1996-06-18 | Scientific Generics Limited | Electrochemical denaturation of double-stranded nucleic acid |
DE69125441T2 (de) | 1990-09-28 | 1997-11-06 | Toshiba Kawasaki Kk | Verfahren zum Gennachweis |
TW279133B (ja) | 1990-12-13 | 1996-06-21 | Elan Med Tech | |
DE4041905A1 (de) | 1990-12-27 | 1992-07-02 | Boehringer Mannheim Gmbh | Testtraeger-analysesystem |
US5455166A (en) | 1991-01-31 | 1995-10-03 | Becton, Dickinson And Company | Strand displacement amplification |
US5273905A (en) | 1991-02-22 | 1993-12-28 | Amoco Corporation | Processing of slide mounted material |
US5264184A (en) | 1991-03-19 | 1993-11-23 | Minnesota Mining And Manufacturing Company | Device and a method for separating liquid samples |
US5279607A (en) * | 1991-05-30 | 1994-01-18 | The State University Of New York | Telemetry capsule and process |
FR2679661B1 (fr) | 1991-07-26 | 1994-10-14 | Sfri | Appareil d'analyse automatique d'echantillons. |
DE69220888T2 (de) | 1991-11-05 | 1998-01-29 | Perkin Elmer Corp | Vorrichtung und Verfahren zur Herstellung von Biopolymeren |
US5270184A (en) | 1991-11-19 | 1993-12-14 | Becton, Dickinson And Company | Nucleic acid target generation |
US5288390A (en) | 1992-03-30 | 1994-02-22 | Sun Company, Inc. (R&M) | Polycyclic aromatic ring cleavage (PARC) process |
AU4047493A (en) | 1992-04-02 | 1993-11-08 | Abaxis, Inc. | Analytical rotor with dye mixing chamber |
AU677781B2 (en) | 1992-05-01 | 1997-05-08 | Trustees Of The University Of Pennsylvania, The | Microfabricated sperm handling devices |
US5744366A (en) * | 1992-05-01 | 1998-04-28 | Trustees Of The University Of Pennsylvania | Mesoscale devices and methods for analysis of motile cells |
US5380487A (en) | 1992-05-05 | 1995-01-10 | Pasteur Sanofi Diagnostics | Device for automatic chemical analysis |
US5357953A (en) | 1992-05-21 | 1994-10-25 | Puritan-Bennett Corporation | Measurement device and method of calibration |
US5318557A (en) | 1992-07-13 | 1994-06-07 | Elan Medical Technologies Limited | Medication administering device |
US5958339A (en) | 1992-08-31 | 1999-09-28 | Clinical Diagnostic Systems, Inc. | Format for immunoassay in thin film |
US5674698A (en) | 1992-09-14 | 1997-10-07 | Sri International | Up-converting reporters for biological and other assays using laser excitation techniques |
DE69320484T2 (de) | 1992-09-14 | 1998-12-24 | Stanford Res Inst Int | "up-converting" reporter molekül für biologische und andere testverfahren unter verwendung von laser anregungstecniken |
US5951300A (en) * | 1997-03-10 | 1999-09-14 | Health Hero Network | Online system and method for providing composite entertainment and health information |
US5478750A (en) | 1993-03-31 | 1995-12-26 | Abaxis, Inc. | Methods for photometric analysis |
JP3563140B2 (ja) | 1995-01-19 | 2004-09-08 | 株式会社日立製作所 | キャピラリーアレイ電気泳動装置 |
KR960703174A (ko) | 1993-06-09 | 1996-06-19 | 미안 알렉 | 자기장 순환식 반응방법(magnetic cycle reaction) |
US5578269A (en) | 1993-06-11 | 1996-11-26 | Ortho Diagnostic Systems Inc. | Automated blood analysis system with an integral centrifuge |
DE69430152T2 (de) | 1993-06-25 | 2002-10-31 | Edward W Stark | Verfahren und Vorrichtung zum Messen von Glukoseverwandten Substanzen |
JP3343156B2 (ja) | 1993-07-14 | 2002-11-11 | アークレイ株式会社 | 光学式成分濃度測定装置および方法 |
GB9315671D0 (en) | 1993-07-29 | 1993-09-15 | Dow Corning Sa | Foam control agents and their use |
KR960704064A (ko) | 1993-08-13 | 1996-08-31 | 죠나단 에스. 도르딕 | 생물학적 활성 화합물의 합성 및 검사를 위한 생체 촉매적 방법(Biocatalytic Methods for Synthesizing and ldentifying Biologically Active Compounds) |
US5397709A (en) | 1993-08-27 | 1995-03-14 | Becton Dickinson And Company | System for detecting bacterial growth in a plurality of culture vials |
CA2129787A1 (en) | 1993-08-27 | 1995-02-28 | Russell G. Higuchi | Monitoring multiple amplification reactions simultaneously and analyzing same |
US6235531B1 (en) | 1993-09-01 | 2001-05-22 | Abaxis, Inc. | Modified siphons for improved metering precision |
US5591643A (en) | 1993-09-01 | 1997-01-07 | Abaxis, Inc. | Simplified inlet channels |
JP3448061B2 (ja) | 1993-09-24 | 2003-09-16 | アボツト・ラボラトリーズ | 自動連続ランダムアクセス分析システムおよびその構成要素 |
JP3391862B2 (ja) | 1993-10-05 | 2003-03-31 | 株式会社日立製作所 | クロマトグラム解析方法 |
JPH07120393A (ja) | 1993-10-13 | 1995-05-12 | Nippon Tectron Co Ltd | 蛍光検出法 |
DE69433695T2 (de) | 1993-11-02 | 2004-08-12 | Matsushita Electric Industrial Co., Ltd., Kadoma | Halbleiterbauelement mit Aggregat von Mikro-Nadeln aus Halbleitermaterial |
US5403415A (en) | 1993-11-17 | 1995-04-04 | Abaxis, Inc. | Method and device for ultrasonic welding |
JPH07151101A (ja) | 1993-11-29 | 1995-06-13 | Kazuo Sugimura | ダイヤフラム接触面が渦巻状の容器 |
JP3504750B2 (ja) | 1993-12-22 | 2004-03-08 | オルソ−クリニカル ダイアグノスティクス,インコーポレイティド | 検量関係式の再校正法及び定量試験キット |
JPH07196314A (ja) | 1993-12-28 | 1995-08-01 | Maruo Calcium Co Ltd | チューブ状合成無機微粒子 |
ATE175723T1 (de) | 1994-03-15 | 1999-01-15 | Scient Generics Ltd | Elektrochemische denatusierung von doppelsträngiger nukleinsäure |
US5590052A (en) | 1994-04-14 | 1996-12-31 | Abaxis, Inc. | Error checking in blood analyzer |
US5648211A (en) | 1994-04-18 | 1997-07-15 | Becton, Dickinson And Company | Strand displacement amplification using thermophilic enzymes |
JP3584990B2 (ja) | 1994-05-09 | 2004-11-04 | タカラバイオ株式会社 | 抗ヒトインフルエンザウイルス抗体 |
US5624850A (en) * | 1994-06-06 | 1997-04-29 | Idetek, Inc. | Immunoassays in capillaries |
US5976896A (en) | 1994-06-06 | 1999-11-02 | Idexx Laboratories, Inc. | Immunoassays in capillary tubes |
US6403367B1 (en) | 1994-07-07 | 2002-06-11 | Nanogen, Inc. | Integrated portable biological detection system |
JP2637695B2 (ja) | 1994-07-12 | 1997-08-06 | 株式会社バイオセンサー研究所 | 溶液吸引器具および吸引式溶液内微量物質測定装置 |
US5639428A (en) | 1994-07-19 | 1997-06-17 | Becton Dickinson And Company | Method and apparatus for fully automated nucleic acid amplification, nucleic acid assay and immunoassay |
US6001229A (en) | 1994-08-01 | 1999-12-14 | Lockheed Martin Energy Systems, Inc. | Apparatus and method for performing microfluidic manipulations for chemical analysis |
US5891734A (en) | 1994-08-01 | 1999-04-06 | Abbott Laboratories | Method for performing automated analysis |
JP3652424B2 (ja) | 1994-10-27 | 2005-05-25 | 日本政策投資銀行 | 自動分析装置及びその方法 |
IE72524B1 (en) * | 1994-11-04 | 1997-04-23 | Elan Med Tech | Analyte-controlled liquid delivery device and analyte monitor |
FI101829B1 (fi) * | 1995-03-07 | 1998-08-31 | Erkki Juhani Soini | Biospesifinen määritysmenetelmä |
US5557596A (en) | 1995-03-20 | 1996-09-17 | Gibson; Gary | Ultra-high density storage device |
US5961923A (en) | 1995-04-25 | 1999-10-05 | Irori | Matrices with memories and uses thereof |
US6352854B1 (en) * | 1995-04-25 | 2002-03-05 | Discovery Partners International, Inc. | Remotely programmable matrices with memories |
US6319668B1 (en) | 1995-04-25 | 2001-11-20 | Discovery Partners International | Method for tagging and screening molecules |
US6340588B1 (en) | 1995-04-25 | 2002-01-22 | Discovery Partners International, Inc. | Matrices with memories |
US5874214A (en) * | 1995-04-25 | 1999-02-23 | Irori | Remotely programmable matrices with memories |
US5832296A (en) * | 1995-04-26 | 1998-11-03 | Interval Research Corp. | Wearable context sensitive user interface for interacting with plurality of electronic devices of interest to the user |
JP3839524B2 (ja) | 1995-06-07 | 2006-11-01 | アジレント・テクノロジーズ・インク | 小型化全分析システム |
US5716852A (en) * | 1996-03-29 | 1998-02-10 | University Of Washington | Microfabricated diffusion-based chemical sensor |
US6168948B1 (en) | 1995-06-29 | 2001-01-02 | Affymetrix, Inc. | Miniaturized genetic analysis systems and methods |
JP3927570B2 (ja) | 1995-07-31 | 2007-06-13 | プレシジョン・システム・サイエンス株式会社 | 容器 |
US6299839B1 (en) | 1995-08-31 | 2001-10-09 | First Medical, Inc. | System and methods for performing rotor assays |
JPH0968533A (ja) | 1995-08-31 | 1997-03-11 | Brother Ind Ltd | 薬品投与量を表示可能な生化学物質測定装置 |
JP3515646B2 (ja) | 1995-09-18 | 2004-04-05 | 大塚電子株式会社 | マルチキャピラリ電気泳動装置 |
JPH09113511A (ja) | 1995-10-18 | 1997-05-02 | Kdk Corp | グリコアルブミン測定用乾式試験片 |
US5687716A (en) | 1995-11-15 | 1997-11-18 | Kaufmann; Peter | Selective differentiating diagnostic process based on broad data bases |
US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
JPH09192218A (ja) | 1996-01-16 | 1997-07-29 | Hitachi Ltd | 血糖値管理システム |
DE19601487C2 (de) | 1996-01-17 | 2001-09-13 | Micronas Gmbh | Vorrichtung zum Behandeln von malignen Gewebsveränderungen |
US5863502A (en) | 1996-01-24 | 1999-01-26 | Sarnoff Corporation | Parallel reaction cassette and associated devices |
CN1096185C (zh) | 1996-01-27 | 2002-12-11 | 三星电子株式会社 | 使用运动和空间相关的隔行向逐行转换装置和方法 |
US5670375A (en) | 1996-02-21 | 1997-09-23 | Biomerieux Vitek, Inc. | Sample card transport method for biological sample testing machine |
US20010044588A1 (en) * | 1996-02-22 | 2001-11-22 | Mault James R. | Monitoring system |
KR19990087449A (ko) | 1996-03-01 | 1999-12-27 | 리차드 웨드레이 | 인플루엔자 바이러스의 검출방법 및 이에 이용되는 화합물 |
JP2988362B2 (ja) * | 1996-03-11 | 1999-12-13 | 株式会社日立製作所 | 多検体分析システム |
JPH09244055A (ja) | 1996-03-14 | 1997-09-19 | Hitachi Ltd | 液晶表示装置 |
US5801057A (en) * | 1996-03-22 | 1998-09-01 | Smart; Wilson H. | Microsampling device and method of construction |
JP2783277B2 (ja) | 1996-03-27 | 1998-08-06 | 日本電気株式会社 | 患者監視装置及び患者監視システム |
JPH09281078A (ja) | 1996-04-09 | 1997-10-31 | Hitachi Electron Eng Co Ltd | Dna塩基配列決定装置 |
US5885470A (en) * | 1997-04-14 | 1999-03-23 | Caliper Technologies Corporation | Controlled fluid transport in microfabricated polymeric substrates |
US5942443A (en) * | 1996-06-28 | 1999-08-24 | Caliper Technologies Corporation | High throughput screening assay systems in microscale fluidic devices |
JP3213566B2 (ja) | 1996-04-26 | 2001-10-02 | アークレイ株式会社 | 検体分析用具およびそれを用いた検体分析方法並びに検体分析装置 |
US5980830A (en) | 1996-05-20 | 1999-11-09 | Sendx Medical, Inc. | Portable modular blood analyzer with simplified fluid handling sequence |
IL118432A (en) | 1996-05-27 | 1999-12-31 | Yissum Res Dev Co | Electrochemical and photochemical electrodes and their use |
US5939291A (en) | 1996-06-14 | 1999-08-17 | Sarnoff Corporation | Microfluidic method for nucleic acid amplification |
CN1173776C (zh) * | 1996-06-28 | 2004-11-03 | 卡钳技术有限公司 | 在微规模流体性设备里的高通过量的筛选分析系统 |
US5797898A (en) * | 1996-07-02 | 1998-08-25 | Massachusetts Institute Of Technology | Microchip drug delivery devices |
EP0818547A1 (en) | 1996-07-10 | 1998-01-14 | Autoliv ASP, Inc. | Recovery of metals values from air bag inflators |
US5874046A (en) | 1996-10-30 | 1999-02-23 | Raytheon Company | Biological warfare agent sensor system employing ruthenium-terminated oligonucleotides complementary to target live agent DNA sequences |
GB9624096D0 (en) | 1996-11-20 | 1997-01-08 | Microbial Systems Ltd | Apparatus and method of use thereof |
US6071249A (en) | 1996-12-06 | 2000-06-06 | Abbott Laboratories | Method and apparatus for obtaining blood for diagnostic tests |
US7590549B2 (en) | 1996-12-23 | 2009-09-15 | Health Hero Network, Inc. | Network media access control system for encouraging patient compliance with a treatment plan |
ATE227844T1 (de) * | 1997-02-06 | 2002-11-15 | Therasense Inc | Kleinvolumiger sensor zur in-vitro bestimmung |
JPH10239240A (ja) | 1997-02-25 | 1998-09-11 | Hitachi Ltd | 自動dnaプローブ装置 |
CA2282623C (en) | 1997-02-28 | 2007-05-22 | Cepheid | Heat exchanging, optically interrogated chemical reaction assembly |
JP3393361B2 (ja) | 1997-03-24 | 2003-04-07 | 国立身体障害者リハビリテーションセンター総長 | バイオセンサ |
GB9706654D0 (en) | 1997-04-02 | 1997-05-21 | Scient Generics Ltd | Disassociation of interacting molecules |
US6235471B1 (en) | 1997-04-04 | 2001-05-22 | Caliper Technologies Corp. | Closed-loop biochemical analyzers |
US6391622B1 (en) * | 1997-04-04 | 2002-05-21 | Caliper Technologies Corp. | Closed-loop biochemical analyzers |
EP0917590A1 (en) | 1997-04-04 | 1999-05-26 | Innogenetics N.V. | Isothermal polymerase chain reaction by cycling the concentration of divalent metal ions |
US5961451A (en) * | 1997-04-07 | 1999-10-05 | Motorola, Inc. | Noninvasive apparatus having a retaining member to retain a removable biosensor |
DE19717023C2 (de) * | 1997-04-23 | 2003-02-06 | Micronas Gmbh | Vorrichtung zum Behandeln von malignen, tumorösen Gewebebereichen |
WO1998049548A1 (en) | 1997-04-25 | 1998-11-05 | Caliper Technologies Corporation | Microfluidic devices incorporating improved channel geometries |
US6406845B1 (en) | 1997-05-05 | 2002-06-18 | Trustees Of Tuft College | Fiber optic biosensor for selectively detecting oligonucleotide species in a mixed fluid sample |
JPH10305016A (ja) | 1997-05-08 | 1998-11-17 | Casio Comput Co Ltd | 行動情報提供システム |
US5985214A (en) | 1997-05-16 | 1999-11-16 | Aurora Biosciences Corporation | Systems and methods for rapidly identifying useful chemicals in liquid samples |
ATE306324T1 (de) | 1997-06-09 | 2005-10-15 | Hoffmann La Roche | Einweg-analysevorrichtung |
AU730827B2 (en) * | 1997-06-09 | 2001-03-15 | Caliper Technologies Corporation | Apparatus and methods for correcting for variable velocity in microfluidic systems |
JPH115756A (ja) | 1997-06-16 | 1999-01-12 | Mitsubishi Chem Corp | 2−アルキルアズレン類の製造方法 |
US5876675A (en) | 1997-08-05 | 1999-03-02 | Caliper Technologies Corp. | Microfluidic devices and systems |
US6368871B1 (en) | 1997-08-13 | 2002-04-09 | Cepheid | Non-planar microstructures for manipulation of fluid samples |
JPH1157560A (ja) | 1997-08-27 | 1999-03-02 | Shin Meiwa Ind Co Ltd | 液体散布車 |
JP2001518624A (ja) * | 1997-09-26 | 2001-10-16 | ユニバーシティ・オブ・ワシントン | 同時の粒子分離および化学反応 |
US5842787A (en) | 1997-10-09 | 1998-12-01 | Caliper Technologies Corporation | Microfluidic systems incorporating varied channel dimensions |
FI107080B (fi) | 1997-10-27 | 2001-05-31 | Nokia Mobile Phones Ltd | Mittauslaite |
US6174675B1 (en) * | 1997-11-25 | 2001-01-16 | Caliper Technologies Corp. | Electrical current for controlling fluid parameters in microchannels |
DE69839709D1 (de) | 1997-12-24 | 2008-08-21 | Cepheid | Vorrichtung und Verfahren zur Lyse |
US6074616A (en) * | 1998-01-05 | 2000-06-13 | Biosite Diagnostics, Inc. | Media carrier for an assay device |
US6200814B1 (en) * | 1998-01-20 | 2001-03-13 | Biacore Ab | Method and device for laminar flow on a sensing surface |
US6861035B2 (en) * | 1998-02-24 | 2005-03-01 | Aurora Discovery, Inc. | Multi-well platforms, caddies, lids and combinations thereof |
US6369893B1 (en) | 1998-05-19 | 2002-04-09 | Cepheid | Multi-channel optical detection system |
WO1999046591A2 (en) | 1998-03-10 | 1999-09-16 | Strategic Diagnostics, Inc. | Integrated assay device and methods of production and use |
US6979424B2 (en) | 1998-03-17 | 2005-12-27 | Cepheid | Integrated sample analysis device |
US7188001B2 (en) | 1998-03-23 | 2007-03-06 | Cepheid | System and method for temperature control |
US6200531B1 (en) | 1998-05-11 | 2001-03-13 | Igen International, Inc. | Apparatus for carrying out electrochemiluminescence test measurements |
WO1999060397A1 (en) * | 1998-05-18 | 1999-11-25 | University Of Washington | Liquid analysis cartridge |
US6287765B1 (en) * | 1998-05-20 | 2001-09-11 | Molecular Machines, Inc. | Methods for detecting and identifying single molecules |
EP0962773A1 (en) | 1998-06-03 | 1999-12-08 | Mark Howard Jones | Electrochemical based assay processes instrument and labels |
US6503231B1 (en) * | 1998-06-10 | 2003-01-07 | Georgia Tech Research Corporation | Microneedle device for transport of molecules across tissue |
JP3389106B2 (ja) | 1998-06-11 | 2003-03-24 | 松下電器産業株式会社 | 電気化学分析素子 |
US7799521B2 (en) * | 1998-06-24 | 2010-09-21 | Chen & Chen, Llc | Thermal cycling |
US6780617B2 (en) | 2000-12-29 | 2004-08-24 | Chen & Chen, Llc | Sample processing device and method |
US6743605B1 (en) | 1998-06-24 | 2004-06-01 | Enzo Life Sciences, Inc. | Linear amplification of specific nucleic acid sequences |
JP2004505857A (ja) | 1998-07-06 | 2004-02-26 | ザ・コカ−コーラ・カンパニー | 一体成型の受け器付きの籠 |
US6214629B1 (en) | 1998-08-06 | 2001-04-10 | Spectral Diagnostics, Inc. | Analytical test device and method for use in medical diagnoses |
US6344333B2 (en) * | 1998-09-08 | 2002-02-05 | Synectig Corporation | Reagent-free immunoassay monitoring electrode assembly |
ATE374833T1 (de) | 1998-11-09 | 2007-10-15 | Eiken Chemical | Verfahren zur synthese von nukleinsäuren |
US6602469B1 (en) | 1998-11-09 | 2003-08-05 | Lifestream Technologies, Inc. | Health monitoring and diagnostic device and network-based health assessment and medical records maintenance system |
US7914994B2 (en) | 1998-12-24 | 2011-03-29 | Cepheid | Method for separating an analyte from a sample |
US6490030B1 (en) | 1999-01-18 | 2002-12-03 | Verification Technologies, Inc. | Portable product authentication device |
US6542717B1 (en) | 1999-01-20 | 2003-04-01 | International Business Machines Corporation | System and method for optimizing personal area network (PAN) electrostatic communication |
GB9903906D0 (en) | 1999-02-19 | 1999-04-14 | Microbiological Res Authority | Method and apparatus for nucleic acid strand separation |
JP4748628B2 (ja) | 1999-02-23 | 2011-08-17 | シーディーエックス ラボラトリーズ インコーポレーテッド | 口腔および類似上皮の病変を検査するための小侵襲の装置 |
US6360888B1 (en) * | 1999-02-25 | 2002-03-26 | Minimed Inc. | Glucose sensor package system |
US8636648B2 (en) | 1999-03-01 | 2014-01-28 | West View Research, Llc | Endoscopic smart probe |
JP3863373B2 (ja) | 1999-03-02 | 2006-12-27 | クオリジエン・インコーポレイテツド | 生物学的流体の分離のための装置を用いる方法 |
EP1129772A3 (en) | 1999-03-03 | 2001-11-07 | Symyx Technologies, Inc. | Fluid distribution for chemical processing microsystems |
US6464687B1 (en) | 1999-03-09 | 2002-10-15 | Ball Semiconductor, Inc. | Implantable drug delivery system |
US6305804B1 (en) | 1999-03-25 | 2001-10-23 | Fovioptics, Inc. | Non-invasive measurement of blood component using retinal imaging |
US20040053290A1 (en) * | 2000-01-11 | 2004-03-18 | Terbrueggen Robert Henry | Devices and methods for biochip multiplexing |
US20020177135A1 (en) * | 1999-07-27 | 2002-11-28 | Doung Hau H. | Devices and methods for biochip multiplexing |
US6942771B1 (en) * | 1999-04-21 | 2005-09-13 | Clinical Micro Sensors, Inc. | Microfluidic systems in the electrochemical detection of target analytes |
JP4085514B2 (ja) | 1999-04-30 | 2008-05-14 | 株式会社島津製作所 | 電気泳動チップ |
US7001725B2 (en) * | 1999-04-30 | 2006-02-21 | Aclara Biosciences, Inc. | Kits employing generalized target-binding e-tag probes |
JP2003523940A (ja) | 1999-05-11 | 2003-08-12 | オーソ−マクネイル ファーマシューティカル インコーポレイテッド | エリスロポエチン投与の薬物速度論的および薬力学的モデリング |
WO2000070350A1 (en) | 1999-05-12 | 2000-11-23 | Cme Telemetrix Inc. | METHOD AND APPARATUS FOR RAPID MEASUREMENT OF HbA¿1c? |
US6544732B1 (en) * | 1999-05-20 | 2003-04-08 | Illumina, Inc. | Encoding and decoding of array sensors utilizing nanocrystals |
DE60014676T2 (de) | 1999-05-28 | 2005-11-17 | Cepheid, Sunnyvale | Vorrichtung und verfahren zur analyse flüssiger proben |
US6818185B1 (en) | 1999-05-28 | 2004-11-16 | Cepheid | Cartridge for conducting a chemical reaction |
EP1181098B2 (en) * | 1999-05-28 | 2011-07-06 | Cepheid | Cartridge for conducting a chemical reaction |
EP1185871A4 (en) | 1999-06-01 | 2003-01-15 | Caliper Techn Corp | MICRO-SCALE ASSAYS AND MICROFLUIDIC DEVICES FOR THE CONTROL OF TRANSPORTER, INDUCED GRADIENT AND BINDING ACTIVITIES |
US6256533B1 (en) | 1999-06-09 | 2001-07-03 | The Procter & Gamble Company | Apparatus and method for using an intracutaneous microneedle array |
AU5877600A (en) | 1999-06-22 | 2001-01-09 | Agilent Technologies Inc. | Apparatus for the operation of a microfluidic device |
US6878540B2 (en) | 1999-06-25 | 2005-04-12 | Cepheid | Device for lysing cells, spores, or microorganisms |
US7195670B2 (en) * | 2000-06-27 | 2007-03-27 | California Institute Of Technology | High throughput screening of crystallization of materials |
US6514769B2 (en) | 1999-07-29 | 2003-02-04 | Jin Po Lee | Multiple analyte assay device with sample integrity monitoring system |
WO2001013127A1 (fr) | 1999-08-11 | 2001-02-22 | Asahi Kasei Kabushiki Kaisha | Cartouche d'analyse et dispositif de regulation d'apport de liquide |
DE60018582T2 (de) * | 1999-08-18 | 2006-01-19 | Microchips, Inc., Bedford | Thermisch aktivierbarer microchip als abgabevorrichtung für chemikalien |
JP2001065458A (ja) | 1999-08-25 | 2001-03-16 | Matsushita Electric Ind Co Ltd | 圧縮機 |
US6858185B1 (en) * | 1999-08-25 | 2005-02-22 | Caliper Life Sciences, Inc. | Dilutions in high throughput systems with a single vacuum source |
EP1210803B1 (en) | 1999-09-09 | 2007-03-21 | Nokia Corporation | Determination of data rate, based on power spectral density estimates |
US20030175992A1 (en) | 1999-09-10 | 2003-09-18 | Anthony Toranto | Glucose assay |
US6251639B1 (en) | 1999-09-13 | 2001-06-26 | Nugen Technologies, Inc. | Methods and compositions for linear isothermal amplification of polynucleotide sequences, using a RNA-DNA composite primer |
US6835184B1 (en) | 1999-09-24 | 2004-12-28 | Becton, Dickinson And Company | Method and device for abrading skin |
EP1849408A3 (en) * | 1999-09-24 | 2007-11-07 | National Research Council of Canada | Method and apparatus for performing intra-operative angiography |
US6368275B1 (en) | 1999-10-07 | 2002-04-09 | Acuson Corporation | Method and apparatus for diagnostic medical information gathering, hyperthermia treatment, or directed gene therapy |
US6743399B1 (en) * | 1999-10-08 | 2004-06-01 | Micronics, Inc. | Pumpless microfluidics |
JP3481578B2 (ja) | 1999-10-12 | 2003-12-22 | 松下電器産業株式会社 | 電子放出素子およびそれを利用した電子源、電界放出型画像表示装置、蛍光灯、並びにそれらの製造方法 |
US6471916B1 (en) * | 1999-11-09 | 2002-10-29 | Packard Instrument Company | Apparatus and method for calibration of a microarray scanning system |
US6361958B1 (en) * | 1999-11-12 | 2002-03-26 | Motorola, Inc. | Biochannel assay for hybridization with biomaterial |
CA2392006C (en) | 1999-11-17 | 2011-03-15 | Microchips, Inc. | Microfabricated devices for the delivery of molecules into a carrier fluid |
JP3441058B2 (ja) | 1999-12-03 | 2003-08-25 | 理化学研究所 | キャピラリーゲル電気泳動用マイクロチップおよびその製造方法 |
JP2001165752A (ja) | 1999-12-06 | 2001-06-22 | Hitachi Ltd | 血清量測定装置および測定方法 |
GB9930000D0 (en) * | 1999-12-21 | 2000-02-09 | Phaeton Research Ltd | An ingestible device |
CA2396893A1 (en) | 2000-01-11 | 2001-08-02 | Clinical Micro Sensors, Inc. | Devices and methods for biochip multiplexing |
IL150810A0 (en) * | 2000-01-19 | 2003-02-12 | Given Imaging Ltd | A system for detecting substances |
DE60135092D1 (de) * | 2000-01-31 | 2008-09-11 | Univ Texas | Tragbare vorrichtung mit einer sensor-array-anordnung |
US7039453B2 (en) * | 2000-02-08 | 2006-05-02 | Tarun Mullick | Miniature ingestible capsule |
KR100542386B1 (ko) | 2000-02-15 | 2006-01-10 | 주식회사 신한은행 | 기업간 대금결제 관리 시스템 및 이를 이용한 기업간대금결제 관리 방법 |
US20030017467A1 (en) * | 2000-02-18 | 2003-01-23 | Aclara Biosciences, Inc. | Multiple-site sample-handling apparatus and method |
CA2399199A1 (en) * | 2000-02-23 | 2001-08-30 | Ring-Ling Chien | Multi-reservoir pressure control system |
ES2420279T3 (es) * | 2000-03-02 | 2013-08-23 | Microchips, Inc. | Dispositivos microfabricados y métodos para almacenamiento y exposición selectiva de productos químicos |
BR0109125A (pt) | 2000-03-09 | 2002-11-26 | Clinical Analysis Corp | Sistema de diagnóstico médico |
US6927851B2 (en) * | 2000-03-31 | 2005-08-09 | Neogen Corporation | Methods and apparatus to improve the sensitivity and reproducibility of bioluminescent analytical methods |
EP1283900A4 (en) | 2000-04-17 | 2006-02-08 | Purdue Research Foundation | BIOSENSOR AND ASSOCIATED METHOD |
US6413213B1 (en) | 2000-04-18 | 2002-07-02 | Roche Diagnostics Corporation | Subscription based monitoring system and method |
US20020052761A1 (en) | 2000-05-11 | 2002-05-02 | Fey Christopher T. | Method and system for genetic screening data collection, analysis, report generation and access |
US6527432B2 (en) | 2000-05-15 | 2003-03-04 | Tecan Trading Ag | Bidirectional flow centrifugal microfluidic devices |
US7006858B2 (en) | 2000-05-15 | 2006-02-28 | Silver James H | Implantable, retrievable sensors and immunosensors |
IL163684A0 (en) | 2000-05-31 | 2005-12-18 | Given Imaging Ltd | Measurement of electrical characteristics of tissue |
AU6501201A (en) * | 2000-06-01 | 2001-12-11 | Science Applic Int Corp | Systems and methods for monitoring health and delivering drugs transdermally |
US7978329B2 (en) * | 2000-08-02 | 2011-07-12 | Honeywell International Inc. | Portable scattering and fluorescence cytometer |
US8383043B2 (en) * | 2004-05-14 | 2013-02-26 | Honeywell International Inc. | Analyzer system |
US7641856B2 (en) | 2004-05-14 | 2010-01-05 | Honeywell International Inc. | Portable sample analyzer with removable cartridge |
US8071051B2 (en) | 2004-05-14 | 2011-12-06 | Honeywell International Inc. | Portable sample analyzer cartridge |
AU2001275290A1 (en) * | 2000-06-07 | 2001-12-17 | Healthetech, Inc. | Breath ketone analyzer |
US6540675B2 (en) * | 2000-06-27 | 2003-04-01 | Rosedale Medical, Inc. | Analyte monitor |
US6603987B2 (en) | 2000-07-11 | 2003-08-05 | Bayer Corporation | Hollow microneedle patch |
JP2002031055A (ja) | 2000-07-14 | 2002-01-31 | Matsushita Electric Ind Co Ltd | 密閉型圧縮機 |
US20020059030A1 (en) | 2000-07-17 | 2002-05-16 | Otworth Michael J. | Method and apparatus for the processing of remotely collected electronic information characterizing properties of biological entities |
EP1304959A1 (en) | 2000-07-24 | 2003-05-02 | Motorola, Inc. | Ingestible electronic capsule |
US7255833B2 (en) | 2000-07-25 | 2007-08-14 | Cepheid | Apparatus and reaction vessel for controlling the temperature of a sample |
JP2002044007A (ja) | 2000-07-26 | 2002-02-08 | Ricoh Elemex Corp | 携帯電話機 |
US20040005582A1 (en) | 2000-08-10 | 2004-01-08 | Nanobiodynamics, Incorporated | Biospecific desorption microflow systems and methods for studying biospecific interactions and their modulators |
US6553244B2 (en) | 2000-08-18 | 2003-04-22 | Cygnus, Inc. | Analyte monitoring device alarm augmentation system |
US20020026111A1 (en) * | 2000-08-28 | 2002-02-28 | Neil Ackerman | Methods of monitoring glucose levels in a subject and uses thereof |
SG100731A1 (en) | 2000-08-30 | 2003-12-26 | Wardlaw Partners Lp | Container for holding biologic fluid for analysis |
AU8857501A (en) | 2000-09-08 | 2002-03-22 | Insulet Corp | Devices, systems and methods for patient infusion |
US7052831B2 (en) * | 2000-09-29 | 2006-05-30 | Becton Dickinson And Company | Detection of multiple analytes from a single sample using a multi-well, multi-analyte flow-through diagnostic test device |
AU2002249481A1 (en) | 2000-10-25 | 2002-08-12 | Exiqon A/S | Open substrate platforms suitable for analysis of biomolecules |
DK1201304T3 (da) | 2000-10-25 | 2006-11-13 | Boehringer Ingelheim Micropart | Mikrostruktureret platform til undersögelse af en væske |
CA2360194C (en) | 2000-10-25 | 2008-10-07 | Micronix, Inc. | A solid state microcuvette using dry films |
US6929636B1 (en) * | 2000-11-08 | 2005-08-16 | Hewlett-Packard Development Company, L.P. | Internal drug dispenser capsule medical device |
JP2002161856A (ja) | 2000-11-28 | 2002-06-07 | Matsushita Electric Ind Co Ltd | シャフトおよびシャフトの製造方法 |
WO2002044703A2 (en) | 2000-12-01 | 2002-06-06 | Cetek Corporation | High throughput capillary electrophoresis system |
AU2002233225A1 (en) | 2000-12-06 | 2002-06-18 | Ecole Polytechnique Federale De Lausanne | Bioanalytical reagent, method for production thereof, sensor platforms and detection methods based on use of said bioanalytical reagent |
GB0030929D0 (en) * | 2000-12-19 | 2001-01-31 | Inverness Medical Ltd | Analyte measurement |
WO2002059625A2 (en) | 2000-12-26 | 2002-08-01 | Weigl Bernhard H | Microfluidic cartridge with integrated electronics |
US6870797B2 (en) | 2001-01-04 | 2005-03-22 | Hewlett-Packard Development Company, L.P. | Media storage system using a transponder for transmitting data signal |
WO2002054052A1 (en) * | 2001-01-08 | 2002-07-11 | Leonard Fish | Diagnostic instruments and methods for detecting analytes |
CA2366802A1 (en) | 2001-01-17 | 2002-07-17 | Bayer Corporation | Method and apparatus for using infrared readings to detect misidentification of a diagnostic test strip in a reflectance spectrometer |
US6878755B2 (en) * | 2001-01-22 | 2005-04-12 | Microgen Systems, Inc. | Automated microfabrication-based biodetector |
JP2004521680A (ja) | 2001-01-22 | 2004-07-22 | ヴイ−ターゲット テクノロジーズ リミテッド | 摂取可能な装置 |
US6484104B2 (en) | 2001-02-15 | 2002-11-19 | Klaus Abraham-Fuchs | Network for evaluating data obtained in a biochip measurement device |
US7567913B2 (en) | 2001-02-16 | 2009-07-28 | Quest Diagnostics Inc. | Method and system for ordering a laboratory test for a patient and obtaining results thereof |
US6612985B2 (en) | 2001-02-26 | 2003-09-02 | University Of Rochester | Method and system for monitoring and treating a patient |
US20020168663A1 (en) * | 2001-02-27 | 2002-11-14 | Phan Brigitte Chau | Methods for DNA conjugation onto solid phase including related optical biodiscs and disc drive systems |
US6949377B2 (en) | 2001-03-05 | 2005-09-27 | Ho Winston Z | Chemiluminescence-based microfluidic biochip |
JP2002266762A (ja) | 2001-03-07 | 2002-09-18 | Matsushita Electric Ind Co Ltd | 冷凍サイクル装置 |
ATE361996T1 (de) | 2001-03-09 | 2007-06-15 | Nugen Technologies Inc | Methoden und zusammensetzungen zur vervielfältigung von rna sequenzen |
JP2002263185A (ja) | 2001-03-12 | 2002-09-17 | Sanyo Electric Co Ltd | 投薬システム及び方法及び投薬装置 |
US6748337B2 (en) | 2001-03-14 | 2004-06-08 | Wardlaw Partners, Lp | Method and apparatus for providing quality control in an instrument for medical analysis |
CA2441206A1 (en) | 2001-03-19 | 2002-09-26 | Gyros Ab | Characterization of reaction variables |
JP2002282217A (ja) | 2001-03-27 | 2002-10-02 | Sysmex Corp | 測定装置及びそれを含む測定結果管理システム |
US7010391B2 (en) | 2001-03-28 | 2006-03-07 | Handylab, Inc. | Methods and systems for control of microfluidic devices |
DE50106580D1 (de) * | 2001-04-12 | 2005-07-28 | Siemens Ag | Verfahren zum Abrechnen von Leistungen in einem Kommunikationsnetz |
US20040142496A1 (en) * | 2001-04-23 | 2004-07-22 | Nicholson Jeremy Kirk | Methods for analysis of spectral data and their applications: atherosclerosis/coronary heart disease |
US7563255B2 (en) * | 2001-05-03 | 2009-07-21 | Massachusetts Eye And Ear Infirmary | Implantable drug delivery device and use thereof |
US20030211618A1 (en) | 2001-05-07 | 2003-11-13 | Patel Gordhandhai Nathalal | Color changing steam sterilization indicator |
MXPA03010209A (es) | 2001-05-09 | 2004-03-16 | Axis Shield Asa | Sistema de analisis. |
US6591124B2 (en) * | 2001-05-11 | 2003-07-08 | The Procter & Gamble Company | Portable interstitial fluid monitoring system |
US20050009101A1 (en) * | 2001-05-17 | 2005-01-13 | Motorola, Inc. | Microfluidic devices comprising biochannels |
WO2002094092A1 (en) * | 2001-05-18 | 2002-11-28 | Polymer Technology Systems, Inc. | Body fluid test apparatus with detachably mounted portable tester |
US6919046B2 (en) | 2001-06-07 | 2005-07-19 | Nanostream, Inc. | Microfluidic analytical devices and methods |
US6767341B2 (en) * | 2001-06-13 | 2004-07-27 | Abbott Laboratories | Microneedles for minimally invasive drug delivery |
JP2002371955A (ja) | 2001-06-15 | 2002-12-26 | Sanuki Kogyo Kk | 往復駆動装置及び該装置を使用した送液ポンプ |
US20030208113A1 (en) | 2001-07-18 | 2003-11-06 | Mault James R | Closed loop glycemic index system |
AU2002367840A1 (en) | 2001-07-26 | 2003-11-17 | Motorola, Inc. | System and methods for mixing within a microfluidic device |
US20030117491A1 (en) * | 2001-07-26 | 2003-06-26 | Dov Avni | Apparatus and method for controlling illumination in an in-vivo imaging device |
WO2003014735A1 (en) * | 2001-08-03 | 2003-02-20 | General Hospital Corporation | System, process and diagnostic arrangement establishing and monitoring medication doses for patients |
JP3775263B2 (ja) | 2001-08-10 | 2006-05-17 | ニプロ株式会社 | 記録媒体およびこの記録媒体を用いた血糖測定システム |
US6823283B2 (en) * | 2001-08-14 | 2004-11-23 | National Instruments Corporation | Measurement system including a programmable hardware element and measurement modules that convey interface information |
US6751491B2 (en) | 2001-09-01 | 2004-06-15 | M Biotech Inc | Analyte measuring biosensor chip using image scanning system |
EP2309253A2 (en) * | 2001-09-05 | 2011-04-13 | Life Technologies Corporation | Apparatus for reading signals generated from resonance light scattered particle labels |
US6966880B2 (en) * | 2001-10-16 | 2005-11-22 | Agilent Technologies, Inc. | Universal diagnostic platform |
JP2003222611A (ja) | 2001-11-20 | 2003-08-08 | Nec Corp | 分離装置、分離方法および分離装置の製造方法 |
US7635588B2 (en) * | 2001-11-29 | 2009-12-22 | Applied Biosystems, Llc | Apparatus and method for differentiating multiple fluorescence signals by excitation wavelength |
JP2003167960A (ja) | 2001-12-04 | 2003-06-13 | Ikuo Kondo | 健康管理システム |
GB0129816D0 (en) * | 2001-12-13 | 2002-01-30 | The Technology Partnership Plc | Testing device for chemical or biochemical analysis |
US7457731B2 (en) | 2001-12-14 | 2008-11-25 | Siemens Medical Solutions Usa, Inc. | Early detection of disease outbreak using electronic patient data to reduce public health threat from bio-terrorism |
AU2002357002A1 (en) * | 2001-12-17 | 2003-06-30 | Powderject Research Limited | Diagnostic sensing apparatus |
KR100491144B1 (ko) * | 2001-12-26 | 2005-05-24 | 삼성에스디아이 주식회사 | 평판표시장치 및 그의 제조방법 |
US20050027182A1 (en) | 2001-12-27 | 2005-02-03 | Uzair Siddiqui | System for monitoring physiological characteristics |
JP2003207454A (ja) | 2002-01-15 | 2003-07-25 | Minolta Co Ltd | 透過光検出装置 |
US20030143551A1 (en) * | 2002-01-30 | 2003-07-31 | Cattell Herbert F. | Reading multiple chemical arrays |
FI112093B (fi) | 2002-01-30 | 2003-10-31 | Boreal Plant Breeding Ltd | Menetelmä ja testipakkaus geneettisen identiteetin osoittamiseksi |
US20040109793A1 (en) | 2002-02-07 | 2004-06-10 | Mcneely Michael R | Three-dimensional microfluidics incorporating passive fluid control structures |
WO2003066906A2 (en) * | 2002-02-07 | 2003-08-14 | Eastern Virginia Medical School Of The Medical College Of Hampton Roads | Diagnostic microarray and method of use thereof |
US7004928B2 (en) | 2002-02-08 | 2006-02-28 | Rosedale Medical, Inc. | Autonomous, ambulatory analyte monitor or drug delivery device |
US20030212379A1 (en) * | 2002-02-26 | 2003-11-13 | Bylund Adam David | Systems and methods for remotely controlling medication infusion and analyte monitoring |
CA2419200C (en) | 2002-03-05 | 2015-06-30 | Bayer Healthcare Llc | Fluid collection apparatus having an integrated lance and reaction area |
US20040122486A1 (en) * | 2002-12-18 | 2004-06-24 | Stahmann Jeffrey E. | Advanced patient management for acquiring, trending and displaying health-related parameters |
JP2005521425A (ja) | 2002-04-01 | 2005-07-21 | フルイディグム コーポレイション | 微小流体粒子分析システム |
US6787108B2 (en) | 2002-04-02 | 2004-09-07 | Cmc Daymark Corporation | Plural intrinsic expiration initiation application indicators |
US7797033B2 (en) | 2002-04-08 | 2010-09-14 | Smart Pill Corporation | Method of using, and determining location of, an ingestible capsule |
US6832296B2 (en) | 2002-04-09 | 2004-12-14 | Ip-First, Llc | Microprocessor with repeat prefetch instruction |
JP2003315348A (ja) | 2002-04-22 | 2003-11-06 | Hitachi High-Technologies Corp | 検体処理システム及びそれを用いた検体検査自動化システム |
US7112444B2 (en) * | 2002-04-24 | 2006-09-26 | Wisconsin Alumni Research Foundation | Method of performing gradient-based assays in a microfluidic device |
US20050177398A1 (en) | 2002-04-25 | 2005-08-11 | Motokazu Watanabe | Dosage determination supporting device, injector, and health management supporting system |
EP1500935A4 (en) * | 2002-04-30 | 2006-05-24 | Arkray Inc | INSTRUMENT OF ANALYSIS |
JP2003322653A (ja) | 2002-05-07 | 2003-11-14 | Toshiba Corp | プローブ固定支持体及びプローブ固定担体 |
US6883957B2 (en) | 2002-05-08 | 2005-04-26 | Cytonome, Inc. | On chip dilution system |
US20030143113A2 (en) | 2002-05-09 | 2003-07-31 | Lifescan, Inc. | Physiological sample collection devices and methods of using the same |
WO2004038363A2 (en) * | 2002-05-09 | 2004-05-06 | The University Of Chicago | Microfluidic device and method for pressure-driven plug transport and reaction |
JP3839349B2 (ja) | 2002-05-15 | 2006-11-01 | 株式会社堀場製作所 | 化学発光酵素免疫測定装置 |
US7125510B2 (en) | 2002-05-15 | 2006-10-24 | Zhili Huang | Microstructure fabrication and microsystem integration |
US7303921B2 (en) * | 2002-05-23 | 2007-12-04 | Gian Paolo Littarru | Method to assay coenzyme Q10 in blood plasma or blood serum |
JP2005529327A (ja) | 2002-06-11 | 2005-09-29 | ケムパック エイ/エス | 液体中に懸濁された粒子を特徴付けるための使い捨てカートリッジ |
JP4106977B2 (ja) | 2002-06-21 | 2008-06-25 | 株式会社日立製作所 | 分析チップ及び分析装置 |
EP1376131A1 (en) * | 2002-06-27 | 2004-01-02 | Inverness Medical Switzerland GmbH | Assay device for liquid sample |
US20040005247A1 (en) | 2002-07-03 | 2004-01-08 | Nanostream, Inc. | Microfluidic closed-end metering systems and methods |
US7470533B2 (en) * | 2002-12-20 | 2008-12-30 | Acea Biosciences | Impedance based devices and methods for use in assays |
US7840421B2 (en) | 2002-07-31 | 2010-11-23 | Otto Carl Gerntholtz | Infectious disease surveillance system |
US7684840B2 (en) * | 2002-08-13 | 2010-03-23 | Given Imaging, Ltd. | System and method for in-vivo sampling and analysis |
CN2559986Y (zh) | 2002-08-23 | 2003-07-09 | 上海博昇微晶科技有限公司 | 集成微流体和微阵列探针的微芯片 |
US7188731B2 (en) | 2002-08-26 | 2007-03-13 | The Regents Of The University Of California | Variable flexure-based fluid filter |
JP2004101381A (ja) | 2002-09-10 | 2004-04-02 | Nittec Co Ltd | 自動分析装置用の複光路セル及びこの複光路セルを用いた分析方法 |
US20040047767A1 (en) * | 2002-09-11 | 2004-03-11 | Richard Bergman | Microfluidic channel for band broadening compensation |
US7282328B2 (en) | 2002-09-20 | 2007-10-16 | New England Biolabs, Inc. | Helicase dependent amplification of nucleic acids |
TW590982B (en) * | 2002-09-27 | 2004-06-11 | Agnitio Science & Technology I | Micro-fluid driving device |
US7186383B2 (en) * | 2002-09-27 | 2007-03-06 | Ast Management Inc. | Miniaturized fluid delivery and analysis system |
US7807197B2 (en) | 2002-09-28 | 2010-10-05 | Mcneil-Ppc, Inc. | Composite dosage forms having an inlaid portion |
US20040064528A1 (en) * | 2002-09-30 | 2004-04-01 | Microsoft Corporation | Safe interoperability among web services |
US7177767B2 (en) | 2002-10-18 | 2007-02-13 | Abaxis, Inc. | Systems and methods for the detection of short and long samples |
US20040086872A1 (en) * | 2002-10-31 | 2004-05-06 | Childers Winthrop D. | Microfluidic system for analysis of nucleic acids |
US7390457B2 (en) | 2002-10-31 | 2008-06-24 | Agilent Technologies, Inc. | Integrated microfluidic array device |
US20040157336A1 (en) * | 2002-11-14 | 2004-08-12 | Affymetrix, Inc. | Automated fluid control system and process |
CN1173182C (zh) | 2002-12-18 | 2004-10-27 | 陕西超英生物医学研究开发有限公司 | 糖尿病自身免疫抗体检测蛋白芯片、其制备及检测方法 |
US20040121305A1 (en) * | 2002-12-18 | 2004-06-24 | Wiegand Roger Charles | Generation of efficacy, toxicity and disease signatures and methods of use thereof |
US20060094108A1 (en) | 2002-12-20 | 2006-05-04 | Karl Yoder | Thermal cycler for microfluidic array assays |
CN102620959B (zh) | 2002-12-26 | 2015-12-16 | 梅索磅秤技术有限公司 | 检定盒及其使用方法 |
US7122153B2 (en) | 2003-01-08 | 2006-10-17 | Ho Winston Z | Self-contained microfluidic biochip and apparatus |
US20050221281A1 (en) | 2003-01-08 | 2005-10-06 | Ho Winston Z | Self-contained microfluidic biochip and apparatus |
US7419638B2 (en) * | 2003-01-14 | 2008-09-02 | Micronics, Inc. | Microfluidic devices for fluid manipulation and analysis |
DE10307030A1 (de) | 2003-02-20 | 2004-09-09 | Eppendorf Ag | Dosiersystem |
US20040176704A1 (en) * | 2003-03-04 | 2004-09-09 | Stevens Timothy A | Collection device adapted to accept cartridge for point of care system |
SE0300823D0 (sv) | 2003-03-23 | 2003-03-23 | Gyros Ab | Preloaded Microscale Devices |
JP4464172B2 (ja) | 2003-03-31 | 2010-05-19 | キヤノン株式会社 | 生化学反応カートリッジ及びその使用方法 |
US7178386B1 (en) * | 2003-04-10 | 2007-02-20 | Nanostream, Inc. | Parallel fluid processing systems and methods |
US7415299B2 (en) * | 2003-04-18 | 2008-08-19 | The Regents Of The University Of California | Monitoring method and/or apparatus |
US7611480B2 (en) | 2003-04-24 | 2009-11-03 | Levy Mark M | Gastrointestinal bioreactor |
JP4487929B2 (ja) | 2003-05-09 | 2010-06-23 | 日本電気株式会社 | 診断支援システムおよび携帯端末 |
JP4260541B2 (ja) | 2003-05-12 | 2009-04-30 | 旭化成ファーマ株式会社 | 糖化タンパク質測定用試験片 |
US20040228765A1 (en) | 2003-05-14 | 2004-11-18 | Witty Thomas R. | Point of care diagnostic platform |
US20040241048A1 (en) | 2003-05-30 | 2004-12-02 | Applera Corporation | Thermal cycling apparatus and method for providing thermal uniformity |
US6789510B1 (en) * | 2003-05-30 | 2004-09-14 | Ru-Ping Lee | Animal restraining apparatus and animal experiment for using the same |
US7258673B2 (en) | 2003-06-06 | 2007-08-21 | Lifescan, Inc | Devices, systems and methods for extracting bodily fluid and monitoring an analyte therein |
EP1637881B1 (en) | 2003-06-20 | 2012-05-02 | Universal Bio Research Co., Ltd. | Sample arraying/assembling device, its method, and apparatus using sample assembly |
JP3918178B2 (ja) | 2003-06-23 | 2007-05-23 | 大阪瓦斯株式会社 | 高純度ナノスケールカーボンチューブ含有炭素質材料の製造法 |
US20050009191A1 (en) | 2003-07-08 | 2005-01-13 | Swenson Kirk D. | Point of care information management system |
JP2005030983A (ja) | 2003-07-09 | 2005-02-03 | Matsushita Electric Ind Co Ltd | 測定装置 |
JP4531698B2 (ja) | 2003-07-17 | 2010-08-25 | 三菱化学メディエンス株式会社 | 自動測定用カートリッジおよびそれを用いる測定装置 |
US7860727B2 (en) | 2003-07-17 | 2010-12-28 | Ventana Medical Systems, Inc. | Laboratory instrumentation information management and control network |
US8346482B2 (en) | 2003-08-22 | 2013-01-01 | Fernandez Dennis S | Integrated biosensor and simulation system for diagnosis and therapy |
CA2537796C (en) * | 2003-09-03 | 2013-12-03 | Life Patch International, Inc. | Personal diagnostic devices and related methods |
US7682833B2 (en) * | 2003-09-10 | 2010-03-23 | Abbott Point Of Care Inc. | Immunoassay device with improved sample closure |
NZ580449A (en) * | 2003-09-11 | 2011-06-30 | Theranos Inc | Ingestible medical device with biocompatible polymer coating, device with microarray to interact with disease marker |
JP4933258B2 (ja) | 2003-09-22 | 2012-05-16 | クイデル コーポレーション | 試料中の複数分析物の検出装置 |
US7524464B2 (en) * | 2003-09-26 | 2009-04-28 | Ahn Chong H | Smart disposable plastic lab-on-a-chip for point-of-care testing |
JP2005104750A (ja) | 2003-09-29 | 2005-04-21 | Matsushita Electric Ind Co Ltd | ナノチューブの精製方法 |
JP4441618B2 (ja) | 2003-10-06 | 2010-03-31 | 独立行政法人産業技術総合研究所 | インフルエンザウイルスの検出方法 |
JP4073023B2 (ja) | 2003-11-07 | 2008-04-09 | 財団法人新産業創造研究機構 | 微小流路デバイスおよびその作製方法 |
KR20050049656A (ko) * | 2003-11-22 | 2005-05-27 | 엘지.필립스 엘시디 주식회사 | 액정표시패널 및 그 제조방법 |
GB0329288D0 (en) * | 2003-12-18 | 2004-01-21 | Inverness Medical Switzerland | Monitoring method and apparatus |
EP1702211A2 (en) | 2003-12-23 | 2006-09-20 | Fastraq, Inc. | Point of care diagnostic platform |
JP2007519484A (ja) | 2004-01-27 | 2007-07-19 | アルティベラ・リミテッド・ライアビリティ・カンパニー | 診断無線周波数識別センサーおよびその適用 |
US7105183B2 (en) | 2004-02-03 | 2006-09-12 | The Regents Of The University Of California | Chlorite in the treatment of neurodegenerative disease |
US20050177057A1 (en) * | 2004-02-05 | 2005-08-11 | Mitchell Friedman | Automated breath collection device |
US20060257941A1 (en) | 2004-02-27 | 2006-11-16 | Mcdevitt John T | Integration of fluids and reagents into self-contained cartridges containing particle and membrane sensor elements |
JP2005291954A (ja) | 2004-03-31 | 2005-10-20 | Olympus Corp | 使い捨て試薬パックとその試薬パックを用いる分析装置 |
US7887750B2 (en) | 2004-05-05 | 2011-02-15 | Bayer Healthcare Llc | Analytical systems, devices, and cartridges therefor |
US8323564B2 (en) * | 2004-05-14 | 2012-12-04 | Honeywell International Inc. | Portable sample analyzer system |
ATE428931T1 (de) | 2004-06-03 | 2009-05-15 | Meso Scale Technologies Llc | Verfahren zur durchführung von vollbluttests |
JP2008502362A (ja) | 2004-06-10 | 2008-01-31 | エージェンシー フォー サイエンス,テクノロジー アンド リサーチ | 鳥インフルエンザウイルスサブタイプh5及びh5n1を検出するための診断用プライマー及び方法 |
US7640048B2 (en) | 2004-07-13 | 2009-12-29 | Dexcom, Inc. | Analyte sensor |
US20060036619A1 (en) | 2004-08-09 | 2006-02-16 | Oren Fuerst | Method for accessing and analyzing medically related information from multiple sources collected into one or more databases for deriving illness probability and/or for generating alerts for the detection of emergency events relating to disease management including HIV and SARS, and for syndromic surveillance of infectious disease and for predicting risk of adverse events to one or more drugs |
CN1311239C (zh) | 2004-09-07 | 2007-04-18 | 李人 | 免疫层析测试条及其制造方法 |
CN102759466A (zh) | 2004-09-15 | 2012-10-31 | 英特基因有限公司 | 微流体装置 |
WO2006036182A2 (en) * | 2004-09-28 | 2006-04-06 | Singulex, Inc. | System and method for spectroscopic analysis of single particles |
EP1817708A4 (en) | 2004-10-18 | 2014-08-27 | Wellstat Vaccines Llc | SYSTEMS AND METHODS FOR OBTAINING, STORING, PROCESSING AND USING IMMUNOLOGICAL INFORMATION RELATING TO AN INDIVIDUAL OR A POPULATION |
US7604985B2 (en) | 2004-11-10 | 2009-10-20 | Becton, Dickinson And Company | System and method for determining fill volume in a container |
WO2006083367A2 (en) | 2004-11-23 | 2006-08-10 | Response Biomedical Corporation | Immunoassay employing two-step internal calibration reaction |
US7396689B2 (en) | 2005-02-04 | 2008-07-08 | Decision Biomarkers Incorporated | Method of adjusting the working range of a multi-analyte assay |
EP1866434B1 (en) | 2005-02-19 | 2013-06-05 | Avacta Group plc | Isothermal nucleic acid amplification |
GB0503836D0 (en) | 2005-02-24 | 2005-04-06 | Axis Shield Asa | Method |
WO2006116455A2 (en) | 2005-04-26 | 2006-11-02 | Applera Corporation | System for genetic surveillance and analysis |
CA2789262C (en) | 2005-04-28 | 2016-10-04 | Proteus Digital Health, Inc. | Pharma-informatics system |
KR101381331B1 (ko) | 2005-05-09 | 2014-04-04 | 테라노스, 인코포레이티드 | 현장진료 유체 시스템 및 그 용도 |
EP3556868A1 (en) | 2005-05-09 | 2019-10-23 | BioFire Diagnostics, LLC | Self-contained biological analysis |
JP4520359B2 (ja) | 2005-05-13 | 2010-08-04 | 日立ソフトウエアエンジニアリング株式会社 | 粒子捕捉装置、並びに粒子配列方法及び粒子配列装置 |
US8020110B2 (en) * | 2005-05-26 | 2011-09-13 | Weisermazars Llp | Methods for defining queries, generating query results and displaying same |
WO2007002579A2 (en) | 2005-06-23 | 2007-01-04 | Bioveris Corporation | Assay cartridges and methods for point of care instruments |
EA007146B1 (ru) | 2005-07-13 | 2006-08-25 | Давид Георгиевич Хидашели | Способ и система анализа характеристик жидких сред биологических организмов |
US20070118399A1 (en) | 2005-11-22 | 2007-05-24 | Avinash Gopal B | System and method for integrated learning and understanding of healthcare informatics |
US8109732B2 (en) * | 2006-01-12 | 2012-02-07 | Nheolis (Sarl) | Horizontal-axis wind generator |
WO2007092713A2 (en) | 2006-02-02 | 2007-08-16 | Trustees Of The University Of Pennsylvania | Microfluidic system and method for analysis of gene expression in cell-containing samples and detection of disease |
CA2643582A1 (en) | 2006-03-10 | 2007-09-20 | Hadas Lewy | Automated sampling and analysis using a personal sampler device |
US8741230B2 (en) | 2006-03-24 | 2014-06-03 | Theranos, Inc. | Systems and methods of sample processing and fluid control in a fluidic system |
WO2007120904A2 (en) | 2006-04-14 | 2007-10-25 | Fuzzmed, Inc. | System, method, and device for personal medical care, intelligent analysis, and diagnosis |
US8007999B2 (en) | 2006-05-10 | 2011-08-30 | Theranos, Inc. | Real-time detection of influenza virus |
CA2657652C (en) | 2006-07-13 | 2015-05-12 | Jody Ann Tirinato | Medical data acquisition and patient management system and method |
US7674616B2 (en) | 2006-09-14 | 2010-03-09 | Hemosense, Inc. | Device and method for measuring properties of a sample |
US20080113391A1 (en) * | 2006-11-14 | 2008-05-15 | Ian Gibbons | Detection and quantification of analytes in bodily fluids |
US20090137047A1 (en) | 2007-03-02 | 2009-05-28 | John Frederick Regan | Automated Diagnostic Kiosk for Diagnosing Diseases |
US20080243394A1 (en) | 2007-03-27 | 2008-10-02 | Theranostics Llc | System, method and computer program product for manipulating theranostic assays |
CN103495439B (zh) * | 2007-05-04 | 2015-09-16 | 欧普科诊断有限责任公司 | 流体连接器和微流体系统 |
US8158430B1 (en) | 2007-08-06 | 2012-04-17 | Theranos, Inc. | Systems and methods of fluidic sample processing |
CN103323610B (zh) | 2007-10-02 | 2016-12-28 | 赛拉诺斯股份有限公司 | 模块化现场护理装置及其应用 |
US8187808B2 (en) | 2008-02-29 | 2012-05-29 | Northwestern University | Barriers for facilitating biological reactions |
WO2009117510A2 (en) | 2008-03-20 | 2009-09-24 | Abaxis, Inc. | Multi-wavelength analyses of sol-particle specific binding assays |
BRPI0910608A2 (pt) | 2008-03-26 | 2016-07-26 | Theranos Inc | métodos e sistemas para avaliar resultados clínicos |
US9779213B2 (en) | 2008-07-25 | 2017-10-03 | Fundacao D. Anna Sommer Champalimaud E Dr. Carlos Montez Champalimaud | System for evaluating a pathological stage of prostate cancer |
US8263006B2 (en) * | 2009-05-31 | 2012-09-11 | Corning Incorporated | Reactor with upper and lower manifold structures |
WO2011106512A1 (en) | 2010-02-26 | 2011-09-01 | Quickcheck Health, Inc. | Method and apparatus for code verified testing |
US20110213579A1 (en) | 2010-02-26 | 2011-09-01 | Henke Tom L | Method and apparatus for verifying test results |
US20110213564A1 (en) | 2010-02-26 | 2011-09-01 | Henke Tom L | Method and apparatus for code verified testing |
US20110213619A1 (en) | 2010-02-26 | 2011-09-01 | Henke Tom L | Method and system for online medical diagnosis |
US20120083501A1 (en) | 2010-09-24 | 2012-04-05 | Hunt Kevin W | Compounds for treating neurodegenerative diseases |
US9061283B2 (en) | 2010-12-03 | 2015-06-23 | Abbott Point Of Care Inc. | Sample metering device and assay device with integrated sample dilution |
WO2013043204A1 (en) | 2011-09-25 | 2013-03-28 | Theranos, Inc. | Systems and methods for collecting and transmitting assay results |
US8380541B1 (en) | 2011-09-25 | 2013-02-19 | Theranos, Inc. | Systems and methods for collecting and transmitting assay results |
US20130080071A1 (en) | 2011-09-25 | 2013-03-28 | Theranos, Inc., a Delaware Corporation | Systems and methods for sample processing and analysis |
US9619627B2 (en) | 2011-09-25 | 2017-04-11 | Theranos, Inc. | Systems and methods for collecting and transmitting assay results |
US20140335505A1 (en) | 2011-09-25 | 2014-11-13 | Theranos, Inc. | Systems and methods for collecting and transmitting assay results |
US10828636B2 (en) | 2016-10-25 | 2020-11-10 | Fannin Partners Llc | Automated remotely instructed driving of an assay |
-
2006
- 2006-03-24 KR KR1020077028881A patent/KR101381331B1/ko active IP Right Grant
- 2006-03-24 KR KR1020137027526A patent/KR101569265B1/ko active IP Right Grant
- 2006-03-24 KR KR1020117006832A patent/KR101322943B1/ko active IP Right Grant
- 2006-03-24 KR KR1020167017039A patent/KR101762424B1/ko active IP Right Grant
- 2006-03-24 NZ NZ59952206A patent/NZ599522A/xx not_active IP Right Cessation
- 2006-03-24 KR KR1020177020579A patent/KR101931899B1/ko active IP Right Grant
- 2006-03-24 KR KR1020137005225A patent/KR101392106B1/ko active IP Right Grant
- 2006-03-24 WO PCT/US2006/011090 patent/WO2006121510A2/en active Application Filing
- 2006-03-24 NZ NZ60361306A patent/NZ603613A/en not_active IP Right Cessation
- 2006-03-24 AU AU2006244617A patent/AU2006244617B2/en active Active
- 2006-03-24 ES ES06748733T patent/ES2820430T3/es active Active
- 2006-03-24 CN CN200680024658.XA patent/CN101535499B/zh active Active
- 2006-03-24 JP JP2008511111A patent/JP2008544214A/ja not_active Withdrawn
- 2006-03-24 US US11/388,723 patent/US20060264779A1/en not_active Abandoned
- 2006-03-24 US US11/389,410 patent/US20060264783A1/en not_active Abandoned
- 2006-03-24 NZ NZ620811A patent/NZ620811A/en not_active IP Right Cessation
- 2006-03-24 CA CA2610294A patent/CA2610294C/en active Active
- 2006-03-24 CA CA3209322A patent/CA3209322A1/en active Pending
- 2006-03-24 MX MX2007013985A patent/MX2007013985A/es active IP Right Grant
- 2006-03-24 NZ NZ564141A patent/NZ564141A/en not_active IP Right Cessation
- 2006-03-24 US US11/388,823 patent/US8841076B2/en active Active
- 2006-03-24 NZ NZ59093006A patent/NZ590930A/xx not_active IP Right Cessation
- 2006-03-24 DE DE20190164.2T patent/DE20190164T1/de active Pending
- 2006-03-24 US US11/388,415 patent/US8679407B2/en active Active
- 2006-03-24 MX MX2015003930A patent/MX340077B/es unknown
- 2006-03-24 KR KR1020147019652A patent/KR101569307B1/ko active IP Right Grant
- 2006-03-24 EP EP20190164.2A patent/EP3763824A1/en active Pending
- 2006-03-24 EP EP06748733.0A patent/EP1883341B1/en active Active
- 2006-03-24 US US11/388,824 patent/US7888125B2/en active Active
- 2006-03-24 KR KR1020157008967A patent/KR101637140B1/ko active IP Right Grant
- 2006-03-24 US US11/389,409 patent/US7635594B2/en active Active
- 2006-03-24 NZ NZ60360406A patent/NZ603604A/en not_active IP Right Cessation
-
2007
- 2007-11-08 MX MX2021011543A patent/MX2021011543A/es unknown
- 2007-11-08 IL IL187272A patent/IL187272A/en active IP Right Grant
-
2009
- 2009-10-08 US US12/576,197 patent/US8283155B2/en active Active
- 2009-11-24 US US12/625,430 patent/US9075046B2/en active Active
-
2011
- 2011-01-07 US US12/986,954 patent/US9182388B2/en active Active
- 2011-10-31 US US13/286,168 patent/US20120052561A1/en not_active Abandoned
-
2012
- 2012-03-30 JP JP2012081306A patent/JP2012127978A/ja active Pending
- 2012-10-08 US US13/647,325 patent/US20130115685A1/en active Pending
- 2012-10-30 JP JP2012238759A patent/JP2013029525A/ja active Pending
-
2013
- 2013-11-14 US US14/080,727 patent/US20140222447A1/en not_active Abandoned
-
2014
- 2014-05-11 IL IL232544A patent/IL232544A/en active IP Right Grant
- 2014-09-09 US US14/481,264 patent/US10761030B2/en active Active
-
2015
- 2015-04-27 JP JP2015089977A patent/JP2015158506A/ja not_active Withdrawn
- 2015-04-27 JP JP2015089978A patent/JP2015158507A/ja active Pending
- 2015-06-01 US US14/727,547 patent/US9772291B2/en active Active
- 2015-09-28 US US14/867,271 patent/US10908093B2/en active Active
-
2017
- 2017-04-24 JP JP2017085342A patent/JP2017142265A/ja active Pending
- 2017-07-24 IL IL253639A patent/IL253639B2/en unknown
- 2017-08-29 US US15/689,905 patent/US11630069B2/en active Active
-
2018
- 2018-04-12 US US15/951,659 patent/US20180231469A1/en active Pending
-
2019
- 2019-09-02 JP JP2019159417A patent/JP2019219416A/ja active Pending
- 2019-09-09 JP JP2019163674A patent/JP2019219420A/ja active Pending
-
2020
- 2020-08-31 US US17/007,334 patent/US20210055226A1/en active Pending
-
2021
- 2021-02-01 US US17/164,032 patent/US20210262940A1/en active Pending
- 2021-09-15 JP JP2021150185A patent/JP2021193390A/ja active Pending
-
2023
- 2023-04-17 US US18/301,835 patent/US20240085338A1/en active Pending
- 2023-10-02 JP JP2023171310A patent/JP2023169427A/ja active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002511965A (ja) * | 1997-07-14 | 2002-04-16 | アボツト・ラボラトリーズ | 遠隔医療 |
JP2002538440A (ja) * | 1999-02-26 | 2002-11-12 | ジェネラル・スキャンニング・インコーポレイテッド | マイクロアレイバイオチップの自動イメージング及び分析 |
JP2003504618A (ja) * | 1999-07-12 | 2003-02-04 | カリパー・テクノロジーズ・コープ. | 化学分析および生化学分析での使用のための光源出力の変調 |
JP2004527825A (ja) * | 2001-02-15 | 2004-09-09 | シーメンス アクチエンゲゼルシヤフト | バイオチップ測定装置で得たデータを評価するためのネットワーク |
JP2003166910A (ja) * | 2001-11-30 | 2003-06-13 | Asahi Kasei Corp | 送液機構及び該送液機構を備える分析装置 |
US20040228766A1 (en) * | 2003-05-14 | 2004-11-18 | Witty Thomas R. | Point of care diagnostic platform |
WO2005024437A1 (ja) * | 2003-09-05 | 2005-03-17 | Nec Corporation | 測定システム |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7423696B2 (ja) | 2017-08-31 | 2024-01-29 | バイオファイア・ダイアグノスティクス,リミテッド・ライアビリティ・カンパニー | アッセイデバイス及びその使用方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2017142265A (ja) | ポイントオブケア流体システムおよびその使用 | |
AU2013201509B2 (en) | Point-of-care fluidic systems and uses thereof | |
AU2017245443A1 (en) | Point-of-care fluidic systems and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170424 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20180119 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180416 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180713 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180912 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181015 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190228 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190522 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190731 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190902 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20191205 |